Functional and structural characterization of the mevalonate diphosphate decarboxylase and the isopentenyl diphosphate isomerase from Enterococcus faecalis by Chen, Chun-Liang
Purdue University
Purdue e-Pubs
Open Access Dissertations Theses and Dissertations
12-2016
Functional and structural characterization of the
mevalonate diphosphate decarboxylase and the




Follow this and additional works at: https://docs.lib.purdue.edu/open_access_dissertations
Part of the Biochemistry Commons, Biology Commons, and the Biophysics Commons
This document has been made available through Purdue e-Pubs, a service of the Purdue University Libraries. Please contact epubs@purdue.edu for
additional information.
Recommended Citation
Chen, Chun-Liang, "Functional and structural characterization of the mevalonate diphosphate decarboxylase and the isopentenyl
diphosphate isomerase from Enterococcus faecalis" (2016). Open Access Dissertations. 947.
https://docs.lib.purdue.edu/open_access_dissertations/947
FUNCTIONAL AND STRUCTURAL CHARACTERIZATION OF 
THE MEVALONATE DIPHOSPHATE DECARBOXYLASE AND 






Submitted to the Faculty of Purdue University 
In Partial Fulfillment of the Requirements for the degree of 
 
Doctor of Philosophy 
 
Department of Biological Sciences 





THE PURDUE UNIVERSITY GRADUATE SCHOOL 
STATEMENT OF DISSERTATION APPROVAL 
Dr. Cynthia V. Stauffacher, Chair 
Department of Biological Sciences 
Dr. Andrew D. Mesecar 
Department of Biological Sciences 
Dr. Michael G. Rossmann 
Department of Biological Sciences 
Dr. Chittaranjan Das 





Dr. Stephen F. Konieczny 
Head of the Departmental Graduate Program 
iii 
 





 I am grateful to my advisor, Dr. Cynthia V. Stauffacher, my research committee, 
Dr. Michael G. Rossmann, Dr. Andrew D. Mesecar, and Dr. Chittaranjan Das, Dr. Lake 
N. Paul, Dr. Greg Costakes, Tim Schmidt and the Stauffacher lab members for sharing 
their scientific experiences with me and mentoring me to think of what science is. It is a 
long journey to become a doctor, and it is just a beginning for me to be serious and 
positive about the science and the life. I would like to thank my parents, Chung-Yung 
Chen, Yueh-Nien Kuo, my parents-in-law, Kuo-Feng Yen and Li-Chiu Wu, and my 
family for all the supports and their waiting for my Ph.D. accomplishment. I especially 
would like to offer sincere thanks to my wife, Yu-Chen Yen, for coming here, sharing 
hard time with me, and supporting my dreams. Whether these dreams will come true or 
not, I will try my best to bring her to a better life. I also want to thank Dr. Stanton Gelvin, 
Dr. Lan-Ying Lee and Dr. Wen-Hong Wang for all the helps here. Without these, I would 
not be able to achieve any success. 
v 
 
TABLE OF CONTENTS 
LIST OF TABLES ............................................................................................................. ix 
LIST OF FIGURES ............................................................................................................ x 
LIST OF ABBREVIATIONS .......................................................................................... xiii 
ABSTRACT ...................................................................................................................... xv 
CHAPTER 1. INTRODUCTION .................................................................................... 1 
1.1 Multi-drug Resistant Enterococci and Nosocomial Infections.................................. 1 
1.2 The Isoprenoid Pathway and the Biosynthesis of IPP and DMAPP in Enterococci . 5 
1.3 Function and Structure of MDD Proteins ................................................................. 8 
1.4 Drug Development against MDDEF ........................................................................ 11 
CHAPTER 2. CRYSTAL STRUCTURE OF MDDEF CO-CRYSTALIZED WITH ATP 
INDICATES THE BINDING OF MVAPP IS CRUCIAL FOR THE BINDING OF ATP 
TO ITS CATALYTICALLY-FAVORED POSITION IN THE ACTIVE SITE OF 
MDDEF  ................................................................................................................ 13 
2.1 Chapter Summary .................................................................................................... 13 
2.2 Introduction ............................................................................................................. 14 
2.3 Materials and Methods ............................................................................................ 15 
2.3.1 Cloning, overexpression and purification of the recombinant form of 
MDDEF  ..................................................................................................................... 15 
2.3.2 Protein crystallization, data collection and structure refinement ................ 16 
2.3.3 Multiple sequence alignment of the MDD family of proteins .................... 20 
2.4 Results ..................................................................................................................... 20 
2.4.1 Protein expression and purification ............................................................. 20 
2.4.2 Protein crystallization, X-ray data collection and structure determination . 23 
2.5 Discussion ............................................................................................................... 29 
CHAPTER 3. CHARACTERIZATION OF THE ENZYME KINETICS OF MDDEF. 31 
3.1 Chapter Summary .................................................................................................... 31 
3.2 Introduction ............................................................................................................. 31 
3.3 Materials and Methods ............................................................................................ 42 
3.3.1 Enzyme kinetics of wild type MDDEF ......................................................... 42 
vi 
 
3.3.2 Inhibition assay ........................................................................................... 42 
3.4 Results ..................................................................................................................... 43 
3.5 Discussion ............................................................................................................... 51 
CHAPTER 4. THERMODYNAMIC STUDIES ON MDDEF BY ISOTHERMAL 
TITRATION CALORIMETRY SUGGEST A SUBSTRATE-INDUCED SUBSTRATE 
BINDING MECHANISM FOR MDDEF .......................................................................... 53 
4.1 Chapter Summary .................................................................................................... 53 
4.2 Introduction ............................................................................................................. 53 
4.3 Materials and Methods ............................................................................................ 59 
4.3.1 Isothermal titration calorimetry (ITC) experiments .................................... 59 
4.3.2 Analysis of ITC data ................................................................................... 60 
4.4 Results ..................................................................................................................... 61 
4.5 Discussion ............................................................................................................... 65 
CHAPTER 5. CRYSTAL STRUCTURES OF THE APO AND LIGAND-BOUND 
FORMS OF MDDEF PROVIDE SNAPSHOTS OF THE MDD ENZYMATIC 
REACTION  ................................................................................................................ 69 
5.1 Chapter Summary .................................................................................................... 69 
5.2 Introduction ............................................................................................................. 70 
5.3 Materials and Methods ............................................................................................ 71 
5.3.1 Protein crystallization, crystal soaking and cryo-protection procedures ..... 71 
5.3.2 Data collection, structure determination, refinement analysis, refinement 
statistics, and substructure determination .................................................................. 72 
5.4 Results ..................................................................................................................... 73 
5.4.1 Soaking experiments for obtaining ligand-bound crystal structures of 
MDDEF  ..................................................................................................................... 73 
5.4.2 Cobalt replacement in enzymatic and crystallographic studies reveal two 
metal binding sites during MDDEF enzyme catalysis ................................................ 82 
5.4.3 Structural comparison provides insight into a detailed substrate binding 
mechanism of MDDEF ............................................................................................... 85 
5.5 Discussion ............................................................................................................... 94 
vii 
 







 .......................................................................................... 94 
5.5.2 A conserved Ser106 residue in Helix 2 functions as an anchoring point for 
metal binding ............................................................................................................. 96 
5.5.3 New insight into a detailed enzyme mechanism of MDDEF ....................... 99 
CHAPTER 6. THE DIMISHED ENZYME ACTIVITYOF THE K187A MUTANT 
REVEALS THE IMPORTANCE OF THE CONSERVED LYSINE IN THE ENZYME 
MECHANISM  .............................................................................................................. 107 
6.1 Chapter Summary .................................................................................................. 107 
6.2 Introduction ........................................................................................................... 107 
6.3 Materials and Methods .......................................................................................... 108 
6.3.1 Site-directed mutagenesis .......................................................................... 108 
6.3.2 Sequence alignment and structural annotation .......................................... 109 
6.3.3 Enzymatic activity of wild type MDDEF and the K187A mutant .............. 110 
6.3.4 Isothermal titration calorimetry (ITC) experiments .................................. 110 
6.4 Results ................................................................................................................... 111 
6.5 Discussion ............................................................................................................. 118 
CHAPTER 7. HIGH-THROUGHPUT SCREENING FOR MDDEF SPECIFIC DRUG 
DISCOVERY  .............................................................................................................. 120 
7.1 Chapter Summary .................................................................................................. 120 
7.2 Introduction ........................................................................................................... 120 
7.3 Materials and Methods .......................................................................................... 121 
7.3.1 Cloning, expression and purification of the recombinant form of Human 
MDD  ................................................................................................................... 121 
7.3.2 Comparison of enzymatic activity of human MDD and wild type MDDEF ....  
  ................................................................................................................... 122 
7.3.3 High-throughput screening for hit selection against MDDEF .................... 123 
7.3.4 Follow-up assays for hit selection against MDDEF ................................... 123 
7.4 Results ................................................................................................................... 124 
7.5 Discussion ............................................................................................................. 130 
viii 
 
CHAPTER 8. STRUCTURE DETERMINATION OF ISOPENTENYL 
DIPHOSPHATE ISOMERASE ..................................................................................... 131 
8.1 Chapter Summary .................................................................................................. 131 
8.2 Introduction ........................................................................................................... 132 
8.3 Materials and Methods .......................................................................................... 135 
8.3.1 Cloning, expression and purification of the recombinant form of IDI-2EF 135 
8.3.2 IDI-2EF protein crystallization, cryo-protection and X-ray data collection 
and analysis .............................................................................................................. 135 
8.4 Results ................................................................................................................... 136 
8.5 Discussion ............................................................................................................. 143 
APPENDIX ..................................................................................................................... 144 
REFERENCES ............................................................................................................... 153 











LIST OF TABLES 
Table 1.1 Structural information of the published structures of MDD from S. epidermidis.
........................................................................................................................................... 10 
Table 2.1 Data collection and refinement statistics of MDDEF-ATP................................ 24 
Table 2.2 Percent identity matrix of the MDD family of proteins.................................... 28 
Table 3.1 Patterns of dead-end inhibition of a bi-substrate reaction ................................ 41 
Table 3.2 Enzyme kinetic parameters ............................................................................... 50 
Table 4.1 Thermodynamic parameters ............................................................................. 65 
Table 4.2 Thermodynamic parameters ............................................................................. 68 
Table 5.1 Data collection and refinement statistics .......................................................... 76 
Table 5.2The interaction profile ....................................................................................... 89 
Table 5.3 Comparison of helix angles in the unbound and bound forms of MDDEF ..... 102 
Table 6.1 Thermodynamic parameters ........................................................................... 117 
Table 7.1 Hits from HTS. ............................................................................................... 127 


















LIST OF FIGURES 
Figure 1.1 The timeline of the introduction of antibiotics and the identification of drug-
resistant gram positive bacteria (staphylococci, streptococci and enterococci).................. 4 
Figure 1.2 The mevalonate pathway and the alternative mevalonate pathway.. ................ 7 
Figure 1.3 The reaction of the decarboxylation of MVAPP to IPP by mevalonate 
diphosphate decarboxylase (MDD). ................................................................................... 8 
Figure 1.4 The overall structure of MDDEF and structure-sequence alignment. .............. 12 
Figure 2.1 Protein purification of MDDEF.. ...................................................................... 22 
Figure 2.2 The superimposition of complex structures of MDDEF-ATP and MDD from 
Staphylococcus epidermidis bound with FMVAPP and ATPS (MDDSE-FMVAPP-
ATPS). ............................................................................................................................. 27 
Figure 3.1 The scheme of the PK/LDH coupled enzyme reaction. .................................. 34 
Figure 3.2 Ping-Pong bi-substrate mechanism.. ............................................................... 36 
Figure 3.3 Sequential random bi-substrate mechanism.. .................................................. 37 
Figure 3.4 Sequential ordered bi-substrate mechanism.. .................................................. 39 
Figure 3.5 Kinetic analysis of MDDEF. ............................................................................. 44 
Figure 3.6 MVAPP and its analogues.. ............................................................................. 45 
Figure 3.7 ATP and its analogues. .................................................................................... 46 
Figure 3.8 Inhibitory assays of MDDEF. ........................................................................... 49 
Figure 4.1 Background of ITC.. ........................................................................................ 55 
Figure 4.2 The role of Asp283 in the proposed mechanism of the MDDSE enzymatic 
reaction. ............................................................................................................................. 57 
Figure 4.3 Superimposition of two tertiary crystal structures of MDD from S. epidermidis 
(4DPT) and its mutant, D283A (4DPW).. ........................................................................ 58 
Figure 4.4 Simulation of ITC thermograms. ..................................................................... 62 
Figure 4.5 The original titration curves from ITC experiments with MDDEF.. ................ 64 
Figure 4.6 The original titration curves from ITC experiments with MDDEF. ................. 67 
Figure 5.1 Structural models of bound forms of MDDEF.. ............................................... 80 










.. ................................................................................................................................. 85 
Figure 5.4 Overlay of unbound and bound forms of MDDEF structures .......................... 88 
Figure 5.5 Movements of Helix 1, 2 and 4 and dynamic residues in the unbound and 
bound forms of MDDEF.. .................................................................................................. 92 







.. ................................................................................................ 95 
Figure 5.7 The structural models of MDD from Staphylococcus epidermidis (MDDSE-
FMVAPP-ATPS, PDB: 4DPT) and Enterococcus faecalis (MDDEF-MVAPP-ADPBeF3-
Mg
2+
). ................................................................................................................................ 97 
Figure 5.8 The 2Fo-Fc and Fo-Fc maps from the complex structure of MDD from 
Staphylococcus epidermidis (MDDSE-FMVAPP-ATPS, PDB: 4DPT).. ........................ 98 
Figure 5.9 A proposed substrate binding model of MDDEF during enzymatic reaction..100 





.. .................. 101 
Figure 5.11 The distance measurement between the in-line phosphoryl transfer donor and 
acceptor.. ......................................................................................................................... 104 
Figure 5.12 A proposed dissociative phosphoryl transfer mechanism of MDDEF during 
the enzymatic reaction.. .................................................................................................. 105 
Figure 6.1 The PCR product of K187A mutant.. ............................................................ 112 
Figure 6.2 Protein purification of K187A mutant.. ......................................................... 113 
Figure 6.3 Relative enzyme activity of the K187A mutant compared to MDDEF.. ........ 114 
Figure 6.4 The original titration curve of ITC experiments.. .......................................... 116 
Figure 6.5 Extracted multiple sequence alignment. ........................................................ 119 
Figure 7.1 The purification profile, SDS-PAGE analysis and the relative enzymatic 
activity comparison. ........................................................................................................ 125 
Figure 7.2 The molecular structures and the IC50 determination of hits from the follow-
up experiments. ............................................................................................................... 129 
Figure 8.1 The methylerythritol phosphate (MEP) pathway and the mevalonate (MVA) 
pathway. .......................................................................................................................... 133 
xii 
 
Figure 8.2 The proposed mechanisms of IPP/DMAPP isomerization by IDI-1(red) and 
IDI-2 (blue).. ................................................................................................................... 134 
Figure 8.3 The purification profile and SDS-PAGE analysis.. ....................................... 137 
Figure 8.4 The cartoon model of the apo-IDI-2EF crystal structure. ............................... 140 
Figure 8.5 IDI-2EF crystallization screening.. ................................................................. 141 







LIST OF ABBREVIATIONS 
   -mercaptoethanol 
APS   Advanced Photon Source 
ATPS   gamma-Thio-ATP 
Co
2+
   cobalt 
G    Gibbs free energy 
H    enthalpy 
S    entropy 
DMAPP  dimethylallyl diphosphate 
DPGP   diphosphoglycolyl proline 
DTT   Dithiothreitol 




GHMP kinase galactokinase, homoserine kinase, mevalonate kinase and 
phosphomevalonate kinase 
HPLC high performance liquid chromatography 
HTS   high-throughput screening 
IDI   isopentenyl diphosphate isomerase 
IPP   isopentenyl diphosphate 
IPTG   isopropyl 1-thio--D-galactopyranoside  
ITC   isothermal titration calorimetry 
Ka    binding constant 
Kd    dissociation constant 
MDD   mevalonate diphosphate decarboxylase 
MDDEF   MDD from Enterococcus faecalis 
MDDSE   MDD from Staphylococcus epidermidis 
MEP pathway  methylerythritol 4-phospahte pathway 
Mg
2+
   magnesium 
MRSA   methicillin-resistant Staphylococcus aureus 
xiv 
 
MVA pathway mevalonate pathway 
TEV protease  recombinant tobacco etch virus protease 






Author: Chen, Chun-Liang. Ph.D. 
Institution: Purdue University 
Degree Received: December 2016 
Title: Functional and Structural Characterization of the Mevalonate Diphosphate 
Decarboxylase and the Isopentenyl Diphosphate Isomerase from Enterococcus 
Faecalis 
Major Professor: Cynthia Stauffacher 
 
 Enterococcus faecalis causes a diverse range of nosocomial infections (in wounds, 
the gastrointestinal tract, the blood stream and the endocardium), and multidrug-resistant 
strains have become a serious issue across countries. Vancomycin, a FDA-approved drug 
for the disruption of the bacterial cell wall biosynthesis, has been utilized to treat 
infectious diseases caused by Enterococci; however, the prevalence of vancomycin-
resistant enterococci (VRE) threatens communities all over the world. We aim at 
developing novel therapeutic strategies to control bacterial growth of Enterococci, and we 
focus on targeting two essential enzymes involved in poly-isoprenoid biosynthesis in 
Enterococcus faecalis; one is the mevalonate diphosphate decarboxylase (MDD) in the 
mevalonate pathway, and the other one is the isopentenyl diphosphate isomerase (IDI), 
which is downstream of MDD. Functional and structural studies on the mevalonate 
diphosphate decarboxylase from Enterococcus faecalis (MDDEF) have been conducted 
using enzymology, isothermal titration calorimetry (ITC) and X-ray crystallography. We 
have used classical enzymology approaches to determine the substrate binding 
mechanism of MDDEF, which belongs to a compulsory bi-substrate mechanism with 
mevalonate diphosphate (MVAPP) binding first. We also obtained thermodynamic data 
on substrate binding in MDDEF using ITC. The results have suggested that enhanced 
xvi 
 
binding of the second substrate, ATP, can be achieved by the prerequisite binding of 
MVAPP. In structure determination, we obtained several crystal structures of MDDEF 
(with or without ligand binding), which represent different states in the enzymatic 
reaction. Based on structural comparisons, structural changes upon substrate binding can 
be observed. Conformational changes in two non-conserved regions during the substrate 
binding event may suggest unique approaches to structure-based specific drug 
development in the near future. In the complex structure of MDDEF bound with MVAPP, 
ADPBeF3 and Mg
2+
, the ordering of two regions (97-104 and 183-191) produces a closed 
conformation which represents a transitional pre-phosphoryl transfer state. The ligand 
architecture implicates a dissociative phosphoryl transfer mechanism during the chemical 
steps of the enzymatic reaction. A high-throughput screening method for identification of 
inhibitors against MDDEF has been established, and the human MDD protein has been 
successfully expressed via auto-induction and purified to homogeneity. Human MDD 
will serve as a selection marker for elimination of non-specific compounds targeting the 
conserved active-site region in MDD proteins. We have also successfully expressed and 
purified the isopentenyl diphosphate isomerase from E. faecalis (IDI-2EF), and have 
obtained crystallization conditions and optimized them for crystallizing apo-form IDI-2EF. 
Diffraction data were collected at the APS synchrotron source where the apo-form crystal 
of IDI-2EF diffracted to a 2.0-Å  resolution. We are doing experiments to obtain the bound 
form of IDI-2EF. These structures can be further utilized for structure-based drug design 
targeting IDI-2EF in the future. In summary, our new findings in MDDEF and IDI-2EF will 
provide the detailed enzyme mechanisms and insight into new therapeutic strategies 
against multi-drug resistant enterococci. 
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CHAPTER 1. INTRODUCTION 
1.1 Multi-drug Resistant Enterococci and Nosocomial Infections 
 After the introduction of penicillin in the 1940s, antimicrobial agents have been 
widely used for treatment of infectious diseases to reduce illness and death. However, 
these disease-causing microbes have adapted to those antimicrobial agents (Fig. 1.1), and 
antimicrobial treatments have become less effective. Multi-drug resistance results from 
the abuse of drugs (no need, improper dosing or duration) in humans and food animals
2
. 
In the United States, a surveillance of antibacterial resistance had been published by 
Centers for Disease Control and Prevention (CDC), reporting the deaths and the cost 
resulted from infectious diseases and emphasizing the urgency to control drug-resistant 
bacteria
3
. These bacteria have been categorized based on the level of concern: urgent 
(Clostridium difficile, carbapenem-resistant Enterobacteriaceae, Neisseria gonorrhoeae), 
serious (multidrug-resistant Acinetobacter, drug-resistant Campylobacter, fluconazole-
resistant Candida, extended spectrum Enterobacteriaceae, vancomycin-resistant 
Enterococcus, multidrug-resistant Pseudomonas Aeruginosa, drug-resistant non-typhoidal 
Salmonella, drug-resistant Salmonella serotype typhi, drug-resistant Shigella, 
methicilline-resistnat Staphylococcus aureus, drug-resistant Streptococcus pneumoniae 
and drug-resistant Tuberculosis) and concerning (vancomycin-resistant Staphylococcus 
aureus, erythromycin-resistant Group A Streptococcus and clindamycin-resistant Group 
B Streptococcus).  Among them, we have focused on Enterococcus faecalis V583, a 
bacterial strain belonging to vancomycin-resistant enterococci causing a range of 
enterococcal infections in clinics, such as bacteremia, urinary tract infections, intra-
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abdominal and pelvic infections, central nerve system infections, skin and skin structure 
infections (SSSIs) and infective enterocaditis
3-5
. 
 Enterococci are Gram-positive and facultative anaerobes colonized in the 
gastrointestinal track. Although they are intrinsically insensitive to detergents and 
antibiotics (clindamycin, cephalosporins and aminoglycosides), most of them are 
considered commensal bacteria. In the past, clinical enterococcal infections were treated 
with vancomycin combined with other antibiotics, such as aminoglycosides. However, 
the emergence of drug-resistant enterococci results in difficulties of treatment
6-8
. The first 
clinical isolates of vancomycin resistant enterococci were reported in Europe in 1988
9,10
. 
Since then, resistant strains have been widely spread around the world. Vancomycin and 
teicoplanin are two kinds of glycopeptides used to treat serious enterococcal infections. 
These two drugs form complexes with the D-Ala-D-Ala terminus of the penta-peptide (L-
Alanine---D-Glutamate---Meso-diaminopimelate---D-Alanine---D-Alanine), prevent the 
following transglycosylation and transpeptidation of the peptidoglycan precursors and 
thus interrupt the cell wall biosysthesis
11
. Two types of replacements, D-Ala-D-lactate 
and D-Ala-D-Ser, have been reported in literature; bacteria with these two elements in the 
construction of the cell wall are considered resistant to vancomycin. D-Ala-D-lactate is 
produced by acquired VanA, VanB, VanD and VanM type resistance; D-Ala-D-Ser is 
produced by acquired VanE, VanG, VanL and VanN type resistance or intrinsic VanC 
type resistance only found in E. gallinarum and E. casseliflavus. Among these, VanA 
type resistance is mostly identified from the VRE infections
11
. VRE are often spread via 
direct contact with people with VRE infections or after contact with VRE-contaminated 
surfaces. The infections often occur among patients who have been hospitalized for long 
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periods of time, previously treated with vancomycin, had weakened immune systems, 
undergone surgical procedures or received medical devices such as urinary or central 
intravenous catheters. 
 Serious infections such as bacteremia and infective endocarditis do require 
treatment with antibiotics. For VRE infections, ampicillin monotherapy or combined 
ampicillin/aminoglycoside (gentamycin or streptomycin) synergy therapy is commonly 
recommended
12,13
. For the treatment of VRE with ampicillin and aminoglycoside 
resistance, linezolid and daptomycin are prescribed. Linezolid and daptomycin are two 
drugs approved by the FDA in 2000 and 2003 for the treatment of infections caused by 
Gram-positive bacteria, especially methicillin-resistant Staphylococcus aureus (MRSA) 
and vancomycin-resistant enterococci (VRE)
14,15
. However, it has been shown 




. Some compounds, such 
as Tedizolid, may be viable treatment options in clinical situations with MDR Gram-
positive pathogens
19
. However, we could expect that those multidrug resistant organisms 
would gain the ability to survive under harsh conditions and selective pressure. For the 
improvement of the health care of patients, new approaches against enterococcal 
infections are urgently needed. Therefore, we need to develop new antimicrobial active 






Figure 1.1 The timeline of the introduction of antibiotics and the identification of 
drug-resistant gram positive bacteria (staphylococci, streptococci and 
enterococci)
9,16,20-44












1.2 The Isoprenoid Pathway and the Biosynthesis of IPP and DMAPP in 
Enterococci 
Thousands of terpenoids, or isoprenoids, identified in nature have been found to be 
responsible for diverse cellular functions in archaea, eukaryotes and prokaryotes. Widely 
known compounds, such as cholesterol and heme in animals
45
, bactoprenol and 
hopanoids in bacteria, and chlorophylls and carotenoids in plants belong to the 
isoprenoids
46
. The basic elements, isopentenyl diphosphate (IPP) and dimethylallyl 
diphosphate (DMAPP), are utilized for poly-isoprenoid biosynthesis through a variety of 
condensation procedures. These two molecules are known to be produced from either the 
mevalonate (MVA) pathway or the methylerythritol 4-phospahte (MEP) pathway
47
, and , 
and both pathways have been found in different organisms. Some organisms (such as E. 
coli) have only the MEP pathway, some have only the MVA pathway (such as human) 
and some have both pathways (such as plants) to synthesize IPP and DMAPP. An 
enzyme, the isopentenyl diphosphate isomerase (IDI), functions to trigger the 
interconversion to adjust the ratio between IPP and DMAPP. For organisms encoding the 
MEP pathway, IPP and DMAPP can be produced directly from the MEP pathway, so IDI 
is thought to be not essential (as in Bacillus subtilis
48
). For organisms with the 
mevalonate pathway, IPP is the only product synthesized from this pathway and the 
DMAPP molecule has to be generated by the IDI enzyme. Thus IDI in such organisms is 
considered essential.  
 In 2000, Wilding et al. reported that the mevalonate pathway is essential in the 
gram positive bacteria, enterococci, staphylococci and streptoccci
49
. This pathway 
includes six enzymes, acetyl-CoA acetyltransferase, HMG-CoA synthase, HMG-CoA 
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reductase, mevalonate kinase, phosphomevalonate kinase and mevalonate diphosphate 
decarboxylase (MDD, EC: 4.1.1.33) (Fig. 1.2). The first three enzymes condense three 
acetyl-CoA molecules into one molecule of mevalonate, and the two kinases sequentially 
add phosphate groups to the 5’ end of mevalonate to produce mevalonate 5’-diphosphate. 
MDDs then trigger the last reaction to produce isopentenyl diphosphate (IPP), which is a 
fundamental building block for synthesis of isoprenoids in bacteria, and is also involved 
in the biosynthesis of bacterial cell wall and electron carriers in the respiratory chain
45,50-
52
. In Streptococcus pneumonia, with the exception of the acetyl-CoA acetyltransferase, 
the rest of the five enzymes in the mevalonate pathway have been identified to be 
essential, suggesting MDD in the mevalonate pathway plays important roles in bacterial 
growth
49
. Experiments in mammals have shown that the ATP-dependent decarboxylation 
of MVAPP catalyzed by MDD is the rate-limiting step in IPP synthesis
53
, implicating 
MDD may serve as a suitable drug target for the disease treatment. Interestingly, in 
Streptococcus pneumonia, an in vitro experiment has indicated that a higher level of 
MVAPP can inhibit mevalonate kinase
54
. This implies the mevalonate pathway is 
sophisticatedly regulated by its downstream products. And this strongly suggests that 
MDD in the mevalonate pathway can be a promising drug target for treatments of 
enterococcal infections. 
 In the literature, an alternative route of the mevalonate pathway has been found in 
some organisms, which have two enzymes, 5-phosphomevalonate decarboxylase and 
isopentenyl phosphate kinase, to build up the alternative mevalonate pathway which 
bypasses the classical mevalonate pathway. This alternative mevalonate pathway first 





 and the production of IPP (Fig. 1.2). The alternative 
mevalonate pathway has now been identified in organisms
55
. As far as we know, the 
genomes of Enterococci encode only the classical mevalonate pathway for IPP 
production, which is consistent with the previous findings on the essentiality of MDD in 
these organisms. 
 
Figure 1.2 The mevalonate pathway and the alternative mevalonate pathway. All the 
molecules are shown in black and enzymes in red. The alternative pathway contains two 
enzymes in the route (blue arrows). HMG-CoA: 3-hydroxy-3-methylglutaryl-CoA; MVA: 
mevalonate; MVAP: mevalonate 5-phosphate; MVAPP: mevalonate 5-diphosphate; IP: 
isopentenyl phosphate; IPP: isopentenyl diphosphate; DMAPP: dimethylallyl 
diphosphate; AACT: acetoacetyl-CoA thiolase; HMGS: HMG-CoA synthase; HMGR: 
HMG-CoA reductase; MVK: mevalonate 5-kinase; PMVK: phosphomevalonate kinase; 
MDD: mevalonate diphosphate decarboxylase; PMVD: phosphomevalonate 
decarboxylase; IPK: isopentenyl phosphate kinase. 
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1.3 Function and Structure of MDD Proteins 
MDD proteins trigger irreversible ATP-dependent decarboxylation of MVAPP to 
produce IPP in the last step of the mevalonate pathway
56
 (Fig. 1.3). A conserved aspartic 
acid (Asp282 in MDD from E. faecalis) has shown to be a catalytic residue for 





Figure 1.3 The reaction of the decarboxylation of MVAPP to IPP by mevalonate 
diphosphate decarboxylase (MDD). Mevalonate-5-diphosphate (MVAPP) and 
magnesium ATP (MgATP) are the two substrates of MDD enzymes. Magnesium ADP 
(MgADP), carbon dioxide (CO2), phosphate and isopentenyl diphosphate (IPP) are 
products. 
 
Although functional and structural analysis has been conducted to reveal several 
key residues in the active site of MDDs for substrate binding and enzyme catalysis
57-59
, 
there are remaining challenges and questions in this field that hamper the progress on 
development of new inhibitors against MDDs and the study of the MDD enzyme 
mechanism at the molecular level. Currently there is no suitable model for explaining 
conformational changes of MDDs upon substrate binding. In 2012, Barta et al had solved 
several crystal structures of MDD from Staphylocuccus epidermidis in complex with 
FMVAPP and ATPS, two analogues of MVAPP and ATP
59
. However, those MDDSE 
structures have not provided a comprehensive understanding on how this enzyme 
responses to substrate binding (Table 1.1). In their structure models, the -thiophosphate 
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of ATPS is far from the 3’-OH group of FMVAPP even though it is in the active site of 
MDDSE. The electron density map of this particular structure, MDDSE-FMVAPP-ATPS 
was defined poorly in the active site region. In their structures, there is no piece of 
evidence for elucidating detailed enzyme catalysis, including the metal binding site(s) 
and the detail chemical steps of MVAPP decarboxylation. There is no structural 
information about how metal ions are involved in MDD enzymatic reaction although it is 
known to be divalent-ion mediated
60
(Table 1.1). Further, lower values of the real-space R 
factor and real-space correlation coefficient of ATPS in the 4DPT and 4DPU structures 
indicate a potentially poorly fit for the ligand (Table 1.1). These suggest that there are 
questions that need to be resolved before utilizing the structural information for rational 
drug design. Before we look into novel structure-based drug development, we will need 
to address these unsolved problems. In our research, we study MDD from Enterococcus 
faecalis (MDDEF) from functional, biophysical and structural points of view in order to 



















PDB accession code 4DPT 4DPU 4DPW 4DU7 
Protein MDDSE* MDDSE MDDSE MDDSE 
Wild type/mutation Wild type S192A D283A Wild type 
Ligands FMVAPP FMVAPP MVAPP MVAPP 
ATPS ATPS ATPS -- 
pH of crystallization condition 7 7 7 7 
Resolution (Å ) 2.2 1.9 2.6 2.2 
Rwork/free 18.0/24.0 17.9/22.4 19.1/25.1 19.1/23.9 
Undefined region 184-193 -- -- 183-186 
Metal ion No No No No 
Distance between 3’-O of 
MVAPP (or FMVAPP) and -P 
of ATPS (Å )** 
5.5 5.9 6.1 -- 
Estimated coordinate error (Å )
#
 0.29 0.24 0.36 0.28 




    
Overall 0.131 / 0.940 0.106 / 0.950 -- 0.119 / 0.946 
FMVAPP 0.222 / 0.942 0.158 / 0.910 -- 0.139 /0.978 
ATPS 0.225 / 0.833 0.183 / 0.828 -- -- 
Interactions between ATPS 
and the phosphate binding loop 
O--NH of 
A105 




*MDD stands for the mevalonate diphosphate decarboxylase and SE stands for Staphylococcus 
epidermidis. **Distance between atoms is measured in Pymol
61
 in each case.# Coordinate error of each 




 Real-space R factor (RSRF) is represented as 
∑ |𝜌𝑜𝑏𝑠 − 𝜌𝑐𝑎𝑙𝑐|
∑ |𝜌𝑜𝑏𝑠 + 𝜌𝑐𝑎𝑙𝑐|
, where obs is the -weighted 2mFo-DFc map and calc is the calculated Fc map, and Real-
space correlation coefficient (RSCC) is calculated between these two density arrays. RSRF and RSCC 

















1.4 Drug Development against MDDEF 
According to the CATH analysis, the overall structure of the MDD family of 
proteins contains and  secondary structure elements (  class) and the folding 
architecture is characterized to a 2-layer sandwich
64
. The protein family annotation 
(Pfam)
65
 indicates MDD proteins belong to the GHMP kinase (galactokinase, homoserine 
kinase, mevalonate kinase and phosphomevalonate kinase) superfamily, which catalyzes 
ATP-dependent reactions. Although mevalonate diphosphate decarboxylases were 
identified and studied several decades ago
56
, there has not been much progress on filling 
the gap between protein structures and specific drug design for application in disease 
control. The reason why this approach to antibiotic development has not been pursued 
might be because the mevalonate pathway exists not only in prokaryotes and archaea, but 
also in eukaryotes, including humans
66
. In the MDD family of proteins, the active site 
environment is highly conserved
67
 (Fig. 1.4), and that could make development of 
specific drugs against MDDEF more challenging. Success in developing drugs specifically 
targeting one member of a family of proteins with similar active sites will rely on subtle 
difference in the actives sites. In the case of virtual high-throughput screening and 
inhibitory studies for identifying selective compounds against the dihydrofolate reductase 
(DHFR) from Pneumocystis carinii
68
, a 25-fold selectivity for Pneumocystis carinii 
DHFR (IC50 = 7 M) over human DHFR (IC50 = 200 M) suggests the importance of 
contacts between compounds and non-identical residues in the active site for compound 
selectivity. It is known that 6-FMVAPP, a substrate analogue of MVAPP, can bind to the 
MVAPP binding pocket of MDD from Staphylococcus epidermidis (PDB code: 4DPT 
and 3QT5)
59,67
. Kinetic studies on MDD from humans (62 nM)
67,69





, yeasts (750 nM)
70
and rats (37 nM)
71
 also show 6-FMVAPP is a competitive 
inhibitor of MVAPP targeting the entire MDD family of proteins with very similar Kis. 
Thus, it is important to develop new strategies to achieve specific drug design against 
MDD since it is, to our best understanding, a promising drug target in the mevalonate 
pathway. We will discuss our experimental results in the following chapters and how they 
provide insight into the connection between the structure and function of MDDEF, which 
will aid in the development of new antibacterial drugs 
 
 
Figure 1.4 The overall structure of MDDEF and structure-sequence alignment. The 
homology model of MDDEF was generated using the apo crystal structure of MDD from 
Staphylococcus epidermidis (3QT5) as a template. Three MDD protein sequences of H. 
sapiens, S.epidermidis and E. faecalis were aligned and the sequence conservation within 
them was color-coded on the homology model in blue (identical), white (similar) and red 
(non-conserved). Active site region is indicated by a green dash-line box and the position 




CHAPTER 2. CRYSTAL STRUCTURE OF MDDEF CO-CRYSTALIZED WITH 
ATP INDICATES THE BINDING OF MVAPP IS CRUCIAL FOR THE 
BINDING OF ATP TO ITS CATALYTICALLY-FAVORED POSITION IN 
THE ACTIVE SITE OF MDDEF 
2.1 Chapter Summary 
The findings from the crystal structures of the mevalonate diphosphate 
decarboxylase from Staphylococcus epidermidis (MDDSE) implied a sequential ordered 
substrate binding mechanism during MDD enzyme catalysis
59
. The substrate binding 
order of the MDD from chicken was first determined in 1987, in which MVAPP was 
suggested to be the first substrate
72
. However, no suitable molecular models were 
available for illustrating the substrate binding mechanism and overall conformational 
changes of the protein upon substrate binding. In this study, we obtained a co-crystal 
structure of MDDEF bound with ATP at a 2.1-Å resolution. In this structure we found that 
the initial binding of ATP leaves the -phosphate outside the active site. By comparing 
our structure with the complex structure of MDDSE bound with two substrate analogues, 
FMVAPP and ATPS (MDDSE-FMVAPP- ATPS)
59
, we observed differences in the 
position of the phosphate binding loop of MDDEF and the phosphate tail of ATP. These 






MDD (EC: 4.1.1.33) acts on MVAPP to produce IPP
56
, and IPP serves as a 
fundamental building block for the synthesis of diverse isoprenoids
45,50
. From the 
enzymatic reaction, we know that MDD proteins have two substrates, MVAPP and ATP 
(Fig. 1.3). The observation from previous structural models of MDDSE bound with 
different ligands suggested that MVAPP is the first substrate, based on the binding site 
located in the deep active site cleft of MDD
59
. Whereas, some key features regarding 
enzyme catalysis were missing in their structures, indicating the structure models might 
not be representing the states during the enzymatic reaction (Table 1.1). Three decades 
ago, the kinetics of MDD proteins isolated from the chicken liver were investigated. The 
enzymology data suggested that MDD proteins a sequential ordered bi-substrate 
mechanism with MVAPP as the first substrate
60,72
. However, there is no comparable 
evidence to support that MDD from Enterococcus faecalis will act on substrates in the 
same manner. And the question we would ask is that if ATP can also bind MDD proteins 
without MVAPP binding to the deeper cleft. There are structures of MDD bound with 
different ligands (Table 1.1), but there is not an MDD structure with ATP or ATP 
analogues alone. Here we aimed to obtain a crystal structure of MDDEF bound with ATP 
to see if there is any difference between MDDEF-ATP structure and those published 
(Table 1.1). With that, we could possible know how the two substrates bind to the active 




2.3 Materials and Methods 
2.3.1 Cloning, overexpression and purification of the recombinant form of MDDEF 
 A gene fragment encoding MDD from Enterococcus faecalis (MDDEF) was 
amplified via PCR and sub-cloned into the expression plasmid pET30a
73
. Upon 
confirmation of the DNA sequence, the construct was transformed into Escherichia coli 
BL21 (DE3). Transformed cells were cultured in LB broth supplemented with kanamycin 
(50 mg/ml) at 37℃ to an A600nm of 1.0. Protein expression of MDDEF was induced by 
addition of isopropyl 1-thio--D-galactopyranoside (IPTG) (0.1 mM) for another 4 hours 
at 37℃. Cells were harvested by centrifugation at 8000 rpm, re-suspended in binding 
buffer (50 mM sodium phosphate at pH 7.4, 300 mM NaCl, and 10 mM imidazole), and 
lysed to homogeneity by French Press. His-tagged MDDEF protein was soluble in the 
supernatant after centrifugation and trapped on a Ni
2+
-NTA column followed by the 
elution with increasing concentrations of elution buffer (50 mM sodium phosphate at pH 
7.4, 300 mM NaCl, and 300 mM imidazole). Eluted collections were pooled and desalted 
against dialysis buffer (25 mM Tris-HCl, pH 8.0, 100 mM NaCl, and 10 mM MgSO4) 
twice, the first one with -mercaptoethanol (2-ME) (20 mM) and the second one without 
2-ME. The N-terminal His-tag was removed from MDDEF by treatment with recombinant 
tobacco etch virus (TEV) protease in dialysis buffer containing 1 mM DTT and 0.5 mM 
EDTA for overnight at 4 ℃ followed by an final dialysis procedure in the dialysis buffer 
without DTT and EDTA. His-tagged TEV and residual His-tagged MDDEF were removed 
by passing the protein mixture through nickel affinity resin. The artificial sequence NA 
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remains at the N terminus of MDDEF after the TEV treatment. The purified MDDEF 
protein solution was concentrated to 8 to 10 mg/ml by ultrafiltration and stored at -20 ℃. 
2.3.2 Protein crystallization, data collection and structure refinement 
 The co-crystal of MDDEF in complex with ATP (MDDEF-ATP) grew under the 
crystallization condition (10 mM ATP, 26% PEG 3350, 50 mM sodium acetate, pH 4.6, 
and 5 mM MgCl2) by sitting drop vapor diffusion. First, ATP was added to the protein 
solution to a final concentration of 10 mM. 1 l of MDDEF-ATP solution was mixed with 
1 l of the reservoir. Crystals formed after a two-day equilibrium. Cryo-protectant (26% 
PEG 3350, 17% PEG 400, 50 mM sodium acetate, pH 4.6, and 5 mM MgCl2) was 
prepared and gradually added into the protein-reserviour mixture to prevent ice formation 
when flash-freezing the crystal in liquid nitrogen. The diffraction data of MDDEF in 
complex with ATP were collected at the 23-ID-D beamline at the Advanced Photon 
Source (APS) in Chicago. The HKL2000 software was used for space group 
determination, data integration, data reduction and data scaling
74
, and after data 
processing, the scalepacked reflection file (.sca) would be generated. The software in 
CCP4, scalepack2mtz, was then used to convert the scalepack reflection file (.sca) to an 
MTZ format (.mtz) with R-free flag assigned (5%)
75
. We then used the molecular-




 The molecular-replacement (MR) method
77,78
 has now been widely employed to 
estimate the phases of an unknown structure from an analogous structure (homologues) 
and the estimated phases were then combined with experimentally derived amplitudes of 
17 
 
structure factors to solve the unknown crystal structure. The fundamental procedure of 
the molecular replacement method composes of the rotation function and the translation 
function, which can be expressed as Equation 2.1, where X is the coordinates of atoms in 
a homologous macromolecule, [R] is the rotation matrix, T is the translation vector and X’ 
is the coordinates of atoms in an unknown structure. 
 




 In the MR method, the problem with searching possible solutions in the six-
dimensional space (Eulerian angles: ,  and ; Cartesian coordinate: x, y and z) can be 
reduced by searching the orientation of the molecule in the step of rotation function, 
followed by searching the position of the molecule in the step of translation function. The 
original rotation function searches a good agreement between two Patterson functions 
corresponding to the unknown and the homologue structures within a certain range (cut-
off radius) in the Patterson space, and the original rotation function is shown in Equation 
2.2,  






where R() is the rotation function, P1 is the Patterson of a model, which will 
rotate by the angles  and then superimposed to P2, the Patterson of the unknown 
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structure. Once the orientation of the unknown structure is determined, the translation 
function will be utilized to search the position of all the molecules in the unit cell until a 
good fit between the predicted structure factors of the model (Fcalc) and the 
experimentally measured structure factors of the unknown structure (Fobs) is obtained. 
The program Phaser in phenix (phenix.phaser) also applies the molecular replacement 
strategy to solve the phase problem and maximum-likelihood methods have been used in 
the rotation and translation functions
79
. 
 We used phenix.phaser to estimate the phases and determine the structure of 
MDD from Enterococcus faecalis. The crystal structure of MDD from Staphylococcus 
epidermidis (MDDSE, PDB: 3QT5) was used as a template to generate a modified search 
model by CHAINSAW in CCP4
80
 for the following molecular replacement. In 
CHAINSAW, a search model can be generated based on the given structure (3QT5) and 
the sequence alignment results (MDDEF aligned to MDDSE), and the mode can be 
selected to create a poly-alanine model or a model with the maximal number of atoms 
common to the target and model residues. The phases of the crystal were determined by 
Molecular Replacement in phenix.phaser
76
 using the poly-alanine structure as a search 
model. In each step of molecular replacement, only one solution was found. The rotation 
function with log-likelihood gain (LLG) greater than 0, the translation function with Z-
score (TFZ) greater than 8 and no violations after the packing analysis also suggest the 
success in solving the phases using molecular replacement. No violation after the packing 
analysis also confirmed the correct selection of the space group.  
 After phase determination by molecular replacement, the first structure refinement 
was performed in phenix.refine
76
. During structure refinement, strategies for refining the 
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model geometry (XYZ coordinates), atomic positions (Real-space), and atomic B factors 
(individual B-factors) were chose, and after the refinement, missing side-chains of the 
residues in the structural model were manually rebuilt in the graphical program Coot
81
 
based on the observation of the electron density map (2Fo-Fc) and the difference map 
(Fo-Fc). Although using a poly-alanine search model can reduce model bias coming from 
the structural model, in the refinement strategies, simulated annealing (Cartesian or 
Torsion angles) was also employed in the first few runs of structure refinement to reduce 
model bias. In phenix, we also used phenix.autobuild to generate density modified maps 
(solvent flattening) and phenix.composit_omit_map to generate the omit map and used 
the maps to evaluate the structural model. In the following refinements, more 
sophisticated options, such as target functions, can be chose for refining the weight 
between X-ray data and the structural model (Optimize X-ray/stereochemistry weight, 
Optimize X-ray/ADP weight). Water molecules were also be built by either phenix.refine 
or Coot, and inspected in the Coot interface. 
 The crystallographic information file (.cif) and the PDB format file (.pdb) of ATP  
were generated using phenix.eLBOW
76
. After few runs of structure refinement (without 
ligands), ATP was manually placed and fitted into the weight difference electron density 
maps (mFo-DFc) in Coot
81
. Geometry and rotamer outliers were gradually reduced after 
several runs of structure refinement and a satisfied structure with ligand(s) was obtained. 
Finally, the ATP molecule in that particular structure would be omitted by setting the 
ligand occupancy to zero or simply removing it from the structure for calculating a 
simulated annealing (SA) ligand omit map using phenix.composite_omit_map, to depict 





2.3.3 Multiple sequence alignment of the MDD family of proteins 
 The sequences of MDD proteins from organisms (Enterococcus faecalis; 
Enterococcus faecium; Staphylococcus epidermidis; Staphylococcus aureus; 
Streptococcus pyogenes; Listeria monocytogenes; Homo sapiens; Trypanosoma brucei; 
Mus. musculus; Xenopus tropicalis; Bos taurus; Arabidopsis thaliana) were aligned using 
EBI Clustal Omega
82
. A pairwise identity score matrix was generated based on the 
sequence alignment results. 
2.4 Results 
2.4.1 Protein expression and purification 
 His-tagged MDDEF was overexpressed in the E. coli (BL21) expression system 
and then purified via nickel-affinity chromatography (Fig. 2.1a). Proteins were eluted 
from the column by elution buffer containing 300 mM imidazole. After the elution, each 
fraction was examined by SDS-PAGE (Fig. 2.1b) and fractions with about 95%-pure 
MDDEF were collected for a following two-step dialysis. The purpose of dialysis is to 
eliminate the imidazole concentration which will affect the protein stability after a freeze-
thaw step in our study. In the first step of dialysis, 2-mercaptoethanol (2-ME) was added 
into the dialysis buffer to a final concentration of 20 mM to avoid protein aggregation, 
and in the second step of dialysis, protein solution was dialyzed against original dialysis 
buffer to get rid of 2-ME. After that, we used an overnight TEV-protease treatment to 
remove the N-terminal His tag in dialysis buffer containing DTT and EDTA. Before 
separating the His-tagged TEV proteases from the His-tag-removed MDDEF by Ni-
21 
 
affinity resin, the protein mixture was dialyzed to remove DTT and EDTA. Finally, we 

























Figure 2.1 Protein purification of MDDEF. (a) The purification profile of MDDEF. The 
detailed procedures of protein purification are discussed in the text. (b) The SDS-PAGE 
gel for the MDDEF protein purification. (M: Protein marker; Pellet: the sample in the 
pellet after French press; Flow through: an aliquot of flow-through containing proteins 
which cannot be trapped on a Ni-NTA column; 5~18: fractions of elution). (c) The SDS-
PAGE gel for the TEV-protease-treatment profile of MDDEF. 0, 4 and *16hrs: TEV 
treatment at different time courses; *: dialysis against buffer without DTT and EDTA; 
RT: treatment at room temperature; Flow through: an aliquot containing proteins which 
cannot be trapped on a Ni-NTA column; Strip: an aliquot after 1 ml of strip buffer 
(containing 50mM EDTA) flowing through the column. 
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2.4.2 Protein crystallization, X-ray data collection and structure determination 
The first crystal structure of MDDEF co-crystallized with ATP (MDDEF-ATP) was 
obtained from a crystal diffracted X-rays to a 2.1-Å  resolution and as collected at the 
APS synchrotron. We used the HKL2000 software to process the data and the resolution 
cut-off for the last shell (highest resolution) was determined based on the data 
completeness (>90%) and I/value (>2). The space group of the crystal was P21212 (a, b, 
c = 82.0, 97.7, 46.3 Å ; ) determined by the software Pointless in CCP4 and 
phenix.phaser
76,83
. One molecule was expected in an asymmetric unit assistant with the 
Mathew coefficient and the water content of that particular crystal (cell volume: 
370710.5 Å
3
, molecular weight: 36489.5 Da, Mathew coefficient: 2.54; % solvent: 51.6). 
A monomeric structure model generated from the crystal structure of MDD from 
Staphylocuccus epidermidis (PDB: 3QT5) was used as a search model for solving phases 
by Molecular Replacement in phenix.phaser. Structure refinement was done in 
phenix.refine and the final Rwork/Rfree was 18.3/21.3. All the statistics of data collection 













Table 2.1 Data collection and refinement statistics of MDDEF-ATP* 
 MDDEF-ATP 
Data collection**  
Space group P21212 
Cell dimensions  
   a, b, c (Å) 82.0, 97.7, 46.3 
()  90.0, 90.0, 90.0 
Resolution (Å) 40.0–2.1 (2.18–2.10) 
Rmeas (%) 7.5 (40.9) 
I /I 14.3 (2.3) 
Completeness (%) 99.8 (99.8) 
Redundancy 4.4 (4.1) 
CC1/2 (%) 92.7 
CC* (%) 98.1 
  
Refinement  
Resolution (Å) 33.6 – 2.1 
No. reflections in test/free R 21102/1140 
Rwork / Rfree (%) 18.3 / 21.3 
Estimated coordinate error (Å) 0.21  
No. atoms  
    Protein 2483 
    Ligand/ion 36 
    Water 160 
B-factors  
    Protein 26.1 
    Ligand/ion 51.0 
    Water 30.8 
R.m.s. deviations  
    Bond lengths (Å) 0.006 




     Most Favored (%) 98.42 
     Allowed (%) 1.58 
     Outliers (%) 0 
*Single crystal grown under the condition containing 10 mM ATP, 26% 
PEG 3350, 50 mM sodium acetate, pH 4.6, and 5 mM MgCl2. 








 In MDDEF-ATP, the overall structure of MDDEF and ATP in the binding pocket 
(Fig. 2.2a) were determined, except for a non-conserved loop (184~192), the 10-4 loop, 
which is between two secondary structure elements, 10 and 4. The simulated-
annealing ligand omit map was generated in phenix.composit_omit_map to demonstrate 
the location and architecture of ATP with less model bias, and the mesh representing the 
electron density of ATP was contoured at 2.5  (Fig. 2.2b). The adenine base of ATP 
forms direct and indirect hydrogen bonds with the conserved residues (Ser93, Asn95 and 
Ser105) which compose the ATP binding pocket (Fig. 2.2b). The ribose group of ATP 
also binds to a water molecule and the backbone carbonyl group of Gln68 in Helix 1. 
The adenosine group of ATP binds to the ATP binding pocket firmly; however, the 
phosphate tail of ATP does not interact with any residues, consistent with its higher 
temperature factor (B-factor > 60) and the poorly defined electron density in this region.  
 By comparing our crystal structure of MDDEF-ATP with the tertiary crystal 
structure of MDD from Staphylococcus epidermidis (MDDSE-FMVAPP-ATPS, PDB 
code: 4DPT), three major differences were observed in the phosphate binding loop (Fig. 
2.2c) and the ATP/ATPS architecture (Fig. 2.2d). The phosphate binding loop in 
MDDEF-ATP has not bent down, if compared with the phosphate binding loop in MDDSE-
FMVAPP-ATPS (Fig. 2.2c), which forms contacts with the -phosphate of ATPS 
through hydrogen bonding (Table 1.1). Second, the -thiophosphate group of ATPS in 
MDDSE-FMVAPP-ATPS was found to form contacts (hydrogen bonding) with the 
backbone amide of two residues, S107 and A108, in Helix 2 (106-121), which are 
located in the active site; instead, the -phosphate of ATP in our structure of MDDEF-ATP 
is facing-out and does not interact with residues in Helix 2 in the active site (Fig. 2.2d). 
26 
 
Third, the  and  phosphates in these two structures have been found to locate at 
different positions and thus the orientation of the phosphate tails in these structures are 
strikingly distinct (Fig. 2.2d).  
 The results from the multiple sequence alignment using EBI Clustal Omega
82
 
show the primary sequences of MDDEF and MDDSE share 60% sequence identity (Table 
2.2), and their active-site key residues involved in the substrate binding and catalysis are 
conserved among the MDD family of proteins. Based on these observations, these two 
homologous proteins are expected to catalyze the same reaction in a similar means. This 
assumption leads to a hypothesis that the binding of another substrate, MVAPP, to the 
active site might induce a change in the conformation for the binding of ATP to its 
catalytically favored position. In the following chapters, we will be testing the hypothesis 



















Figure 2.2 The superimposition of complex structures of MDDEF-ATP and MDD 
from Staphylococcus epidermidis bound with FMVAPP and ATPS (MDDSE-
FMVAPP-ATPS). (a) A cartoon model of the crystal structure of MDDEF-ATP is shown 
in pink and the ATP molecule as a stick model. (b) The ATP molecule is surrounded by 
the ligand omit map (mFo-DFc at a contour of 2.5). Residues and waters (red spheres) 
involved in the ATP binding are depicted. (c) An overlay of the cartoon models of 
MDDSE-FMVAPP-ATPS (PDB: 4DPT, green) and MDDEF-ATP (pink) (r.m.s.d. 
=0.663Å) are depicted with the phosphate binding loops emphasized (thickened lines). 
(d) Ligands from the two structures are shown as stick models (FMVAPP and ATPS 
from MDDSE-FMVAPP-ATPS; ATP and SO4
2-
 from MDDEF-ATP). The arrows in green 
and pink indicated the distinct orientations of the phosphate tails of ATPS and ATP in 



















































 In 2012, Barta et. al. reported experimental findings on the substrate binding order 
of MDDSE. Based on the geometric properties of the two substrate binding pockets, they 
proposed the MDDSE substrate binding model belongs to an ordered bi-substrate 
mechanism in which the MVAPP is the first substrate. However, a few issues remain 
unsolved from their structural results. First, the 10-4 loop could not be determined in 
their complex structure of MDDSE-FMVAPP-ATPS (Table 1.1). A conserved lysine in 
this loop has not yet been annotated, although it was suggested to be important for 
catalysis via mutagenesis study in MDD from rats
58
. Second, MDD proteins have been 
known to trigger the ATP-dependent decarboxylation of MVAPP, but with a requirement 
for metal ions (Mg
2+
) to perform catalysis under physiological conditions
60
. However, in 
their structures, there is no structural evidence to suggest the location of metal binding 
sites. Third, the thiophosphate group of ATPS, although in the active site, has been 
found to be too far from the 3’-OH group of MVAPP (5.5 Å ) for catalysis (Table 1.1), 
which has been proposed to be the phosphate acceptor during phosphoryl transfer from 
ATP to MVAPP. Based on the observations above, we could argue that the structure 
models of MDDSE were not complete and the substrate binding model for the MDD 
family of proteins remains unestablished. In the future, this could also be a problem for 
structure-based drug design which is heavily dependent on accurate atomic models of 
macromolecules. Interestingly, ATP can also bind to the ATP binding pocket of MDDEF 
alone in our structure of MDDEF-ATP. However, an outward facing phosphate tail of 
ATP and the position of the phosphate binding loop indicate that the architecture of ATP 
is not for enzyme catalysis, suggesting the binding of MVAPP might be a prerequisite 
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step in the enzymatic reaction cycle. This actually encourages us to work on the 
determination of the substrate binding model and the structures of unbound and ligand-
bound MDDEF. 
 Interestingly, in our crystal structure of MDDEF-ATP, the ATP molecule does not 
have magnesium bound to the - and -phosphate group. In the crystallization condition, 
we have 5 mM magnesium chloride and 10 mM ATP in the solution. The buffer condition 





. The dissociation constant between HATP
3-
 and magnesium is 
about 1.58 mM (log Ka = 2.79 ± 0.15)
85
, and the MgHATP concentration under this 
condition is about 4 mM, suggesting the concentration of free HATP
3-
 is about 6 mM. 
The reason for not seeing magnesium-bound ATP in the crystal structure of MDDEF-ATP 
could be due to the competitive binding of free HATP
3-
 to the ATP binding pocket of 
MDDEF, or a higher average of temperature factor of the phosphate tail of ATP (B) results 
in poorly defined electron density in this region so that we cannot claim a magnesium ion 














CHAPTER 3. CHARACTERIZATION OF THE ENZYME KINETICS OF MDDEF 
3.1 Chapter Summary 
 The crystal structure of MDDEF-ATP described in the previous chapter implied 
that the binding of MVAPP cause changes in the protein that could affect the binding of 
ATP. In previous work with avian MDD, the substrate binding order of MDD has been 
suggested to be an ordered bi-substrate mechanism with MVAPP binding first
72
. In our 
study, we wanted to know if the overall enzyme mechanism was conserved in the 
bacterial enzyme MDD so that we could interpret the conformational changes upon 
substrate binding observed in crystals of MDDEF in complex with different ligands. We 
have done the enzymatic activity assays at varied concentrations of both substrates, 
MVAPP and MgATP, to confirm that the MDDEF enzymatic reaction belongs to a 
sequential bi-substrate mechanism. Then we utilized ATPS, an ATP analogue, to 
determine that MVAPP is the first substrate bound based on the inhibitory pattern of 
increasing ATPS in the reaction. With this information, we can now characterize the 
conformational changes observed in MDDEF complex structures with an ordered 
substrate/ligand binding event. 
3.2 Introduction 
 MDD proteins trigger the decarboxylation of MVAPP to produce IPP and this 
reaction is coupled with the conversion of ATP to ADP. Sequence and structure analysis 





. So far, several crystal structures of MDD proteins from prokaryotes and 
eukaryotes have been determined and published in literature
59,67,69
. In a structure analysis 
of the MDDSE in complex with different ligands, MVAPP is the first substrate bound 
since its binding pocket is located more deeply in the active site of MDD than the binding 
pocket of ATP
59
. One eukaryotic MDD protein from chicken was examined via 
enzymology approaches few decades ago to determine the substrate binding order of 
MDD; these results also suggested MVAPP is the first substrate
72
. However, from our 
crystal structure of MDDEF-ATP, ATP can also bind to the ATP binding pocket by itself, 
even if in an unproductive form (Fig. 2.2b). The question comes to us whether the 
substrate binding order is conserved in both eukaryotic and prokaryotic MDD proteins. 
The determination of the substrate binding order of MDDEF will allow us to design 
experiments for obtaining the crystal structures of MDDEF in complex with ligands in an 
ordered manner, and hopefully obtain structural snapshots of different states in the MDD 
catalytic reaction. In order to achieve our goal, the first step is to establish the functional 
assay for examining the MDDEF enzymatic function. 
 MDD proteins act on MVAPP and ATP to produce IPP, ADP, CO2 and PO4
2-
. 
Ideally, the activity can be directly measured by detecting the production of any of the 
individual products. However, detecting the production of CO2 is not plausible for the 
future high-throughput drug screening against MDDEF. Although free phosphate can be 
detected via the malachite green assay method, in our preliminary tests, this method is not 
sensitive when the phosphate concentration is more than 10 M. In addition, ATP in 
solution is labile and undergoes hydrolysis under acidic conditions used in the malachite 
green assay, which could severely affect the readout and results. As for the detection of 
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IPP, high performance liquid chromatography (HPLC) has been used to separate IPP 
from MVAPP and the method could not be transformed to HTS
86
.  
 In the literature, the coupled enzyme method (pyruvate kinase/lactate 
dehydrogenase) has been widely used for monitoring ADP production, and this method 
has also been applied for measuring the MDD enzymatic activity
58,60,67
 (Fig. 3.1). In this 
assay, ADP produced from the MDD reaction is converted back to ATP by pyruvate 
kinase, coupled with the conversion of phosphoenolpyruvate to pyruvate, and the 
pyruvate is then converted to lactate by lactate dehydrogenase, coupled with the 
oxidation of NADH to NAD
+
. The oxidation of NADH to NAD
+
 results in an absorbance 
decrease at 340nm. Thus the ADP production can be detected by measuring the decrease 
in OD340nm. The MDD enzymatic activity would be proportional to the slope of the 
continuously declining value of OD340nm. We have utilized this method to determine the 














Figure 3.1 The scheme of the PK/LDH coupled enzyme reaction. MDDEF performs 
the ATP-dependent decarboxylation of mevalonate 5-diphospahte (MVAPP) to produce 
isopentenyl diphosphate (IPP), carbon dioxide (CO2), phosphate and ADP. Magnesium 
(Mg
2+
) is a cofactor that binds to ATP and ADP with a Kd value of 20 M
85
. The 
PK/LDH coupled reaction serves as a reporting system for measuring the production of 
ADP, which corresponds to the enzymatic rate of MDDEF. The decrease of absorbance at 
340nm indicates the oxidation of NADH to NAD+, which is coupled with the 
regeneration of ADP to ATP. 
 The MDD enzymatic reaction belongs to a bi-substrate mechanism, in which 
MVAPP and ATP are its two substrates. Bi-substrate enzymatic reactions can be roughly 
divided into two major categories: the ping-pong and the sequential bi-substrate 
mechanisms, and the binding of two substrates in a sequential mechanism can be either 
an ordered or random binding event. For a ping-pong bi-substrate reaction, the free 
enzyme (E) will first act on the first substrate (A) to produce the first product (P), and the 
intermediate form of the enzyme (E*)  will further act on the second substrate (B) and 
produce the second product (Q), followed by the next reaction (Fig. 3.2a). For studying 
the enzyme kinetics, kinetic data will be represented by Equation 3.1, where v is a value 
of determined enzyme activity under certain condition, [A] and [B] are the concentrations 




 are kinetic parameters. Kinetic data will be 
analyzed and represented by Lineweaver-Burk plots, and an enzyme with a ping-pong bi-
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substrate reaction will show a parallel-line characteristic in a Lineweaver-Burk plot (Fig. 
3.2b), and in this case, A will be the first substrate in a ping-pong reaction. 
 
 
              Equation 3.1 
 
 
For a sequential random bi-substrate reaction, the free enzyme (E) can bind either of 
two substrates (A or B) first; the first tertiary complex (E˙A˙B) will form followed by 
catalysis, which results in the formation of the second complex (E˙P˙Q), where P and Q 
are two products which can be released randomly (Fig. 3.3a). Kinetic data in this case 
will be represented by Equation 3.2, analyzed by Lineweaver-Burk plots and the 
simulated results are shown in Fig. 3.3b, in which kinetic lines in a Lineweaver-Burk plot 









Figure 3.2 Ping-Pong bi-substrate mechanism. (a) The scheme of a ping-pong bi-
substrate mechanism. (E: enzyme; A and B: substrates; P and Q: products). (b) Kinetic 
data analyzed by a Lineweaver-Burk plot indicates a ping-pong bi-substrate mechanism, 
where parallel lines represent kinetic measurements of the enzymatic activity at several 





Figure 3.3 Sequential random bi-substrate mechanism. (a) The scheme of a sequential 
random bi-substrate mechanism. (E: enzyme; A and B: substrates; P and Q: products). (b) 
Enzymatic reactions are conducted at several fixed concentrations of substrate B and 
varying concentrations of substrate A. Kinetic data are represented by Equation 3.2 and 







 For a sequential ordered bi-substrate reaction, the enzyme (E) binds to the first 
substrate (A), followed by the binding of the second substrate (B). The first tertiary 
complex (E˙A˙B) will form and catalysis occurs and results in the formation of the 
second complex (E˙P˙Q), where P and Q are two products, which could be released in an 
ordered manner (Fig. 3.4a). For a rapid-equilibrium reaction, in which the enzyme 
catalysis step is a rate-limiting step, kinetic data will be represented by Equation 3.3, and 
kinetic lines converge to the y axis (Fig. 3.4b). For a steady-state reaction, in which the 
velocity of enzyme catalysis is similar to that of substrate binding, the data will be 
represented by Equation 3.4, and kinetic lines converge to x axis, similar to that in a 















Figure 3.4 Sequential ordered bi-substrate mechanism. (a) The scheme of a sequential 
ordered bi-substrate mechanism. (E: enzyme; A and B: substrates; P and Q: products). (b) 
For a rapid-equilibrium reaction, enzymatic reactions are conducted at several fixed 
concentrations of substrate B and varying concentrations of substrate A. Kinetic data are 
represented by Equation 3.4 and the Lineweaver-Burk plot analysis shows kinetic lines 
converging to the y axis. (c) For a steady-state reaction, enzymatic reactions are 
conducted at several fixed concentrations of substrate B and varying concentrations of 
substrate A. Kinetic data are represented by Equation 3.5 and the Lineweaver-Burk plot 
analysis shows kinetic lines converging to the x axis. 
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 Lineweaver-Burk plots of a reaction that belongs to the ping-pong mechanism 
will yield a set of parallel lines, as seen in Figure 3.2b. Instead, if a reaction conforms to a 
sequential mechanism, kinetic lines will converge in Lineweaver-Burk plots (Fig. 3.3b, 
Fig. 3.4b and c). Thus, to differentiate the mechanism of a reaction, first of all, we would 
need to perform a set of enzymatic reactions at varying concentrations of both substrates 
and utilize the Lineweaver-Burk plotting method to analyze the data. Second, if the 
mechanism of a reaction belongs to a sequential bi-substrate mechanism (except for a 
rapid-equilibrium sequential ordered mechanism), the kinetic data will be represented by 
the general equation for a bi-substrate system (Equation. 3.5), and we will need a 
substrate analogue as a dead-end inhibitor to obtain inhibitory patterns and determine the 
substrate binding order based on the patterns presented in Table 3.1. For example, if a set 
of enzymatic reactions were performed for an enzyme at varied concentrations of both 
substrates and the kinetic lines were shown to converge to the x axis in a Lineweaver-
Burk plot, the enzyme mechanism of that particular enzyme belongs to a sequential bi-
substrate mechanism; however, substrate binding events could be either random or 
ordered. If A is suspected to be the first substrate in the reaction, a substrate analogue 
mimicking B can be used in the inhibitory assays for obtaining unique patterns (varied 
[A]: uncompetitive; varied [B]: competitive, Table 3.1). Using a substrate analogue 
mimicking A in inhibitory assays will obtain inhibitory patterns (varied [A]: competitive; 
varied [B]: noncompetitive, Table 3.1) similar to the inhibitory patterns in a sequential 
random bi-substrate mechanism (Table 3.1). It should be mentioned that the inhibitory 
patterns of a sequential ordered bi-substrate mechanism derived from the experiments 
using a second substrate analogue as a dead-end inhibitor have no difference from the 
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derived inhibitory patterns of a ping-pong bi-substrate mechanism, so it is required to 
perform enzymatic reaction at varying concentrations of both substrates to differentiate 
whether a mechanism belongs to a sequential or ping-pong bi-substrate reaction in the 






Table 3.1 Patterns of dead-end inhibition of a bi-substrate reaction* 
Mechanism Competitive inhibitor 
mimicking a substrate  
Inhibition pattern** 
Varied [A] Varied [B] 
Sequential ordered 
with A binding first 
A Competitive Noncompetitive 
Sequential ordered 
with A binding first 
B Uncompetitive Competitive 
Sequential ordered 
with B binding first 
A Competitive Uncompetitive 
Sequential ordered 
with B binding first 
B Noncompetitive Competitive 
Sequential random A Competitive Noncompetitive 
Sequential random B Noncompetitive Competitive 
Ping-Pong A Competitive Uncompetitive 
Ping-Pong B Uncompetitive Competitive 
*The table is modified from Table 11.2 in the text book “Enzymes: A Practical Introduction to 
Structure, Mechanism and Data Analysis” edit by Robert A. Copeland
87
. 





3.3 Materials and Methods 
3.3.1 Enzyme kinetics of wild type MDDEF 
 Enzymatic activity of MDDEF was determined using an ATP/NADH enzyme-
coupled assay. Each reaction was performed at 30℃ under the buffer condition (100 mM 
HEPES, pH 7.0, 100 mM KCl, 10 mM MgCl2, 0.2 mM NADH, 0.4 mM 
phosphoenolpyruvate, 4 units of pyruvate kinase, 4 units of lactate dehydrogenase, and 
100 nM MDDEF
59
). Initial velocity of each reaction was determined at a range of 
concentrations of MgATP (50, 100, 150, 200, 400, 600, 800 and 1000 M) and MVAPP 
(10, 15, 25, 50, 100, 150, 200 and 300 M). Enzymatic parameters, Km and Vmax, were 
determined by fitting kinetic data to a sequential bi-substrate mechanism model using 
SigmaPlot12.5/Enzyme Kinetic Module 1.3 (Systat Software, Inc.). 
3.3.2 Inhibition assay 
 ATPS was used as a competitive inhibitor of ATP for determining the inhibition 
kinetics of MDDEF. Different fixed concentrations of ATPS (0, 100, 200 and 400 M) 
were added into the reactions versus varying MgATP (50, 100, 200 and 400 M) and 
fixed MVAPP (40 M), or varying MVAPP (10, 20, 40, 80 M) and fixed MgATP (200 
M). Assays were performed under the condition as described above. The kinetic data 
with a fixed MVAPP concentration were fit into a competitive inhibition model; the 
kinetic data with a fixed MgATP concentration were fit into an uncompetitive inhibition 




 We have performed enzymatic reactions at varying concentrations of both 
substrates of MDDEF, MgATP and MVAPP (Fig. 3.5a and c), and analyzed the kinetic 
data by the Lineweaver-Burk method (Fig 3.5b and d). Each 1/v (reciprocal of reaction 
velocity) was plotted as a function of either 1/[MVAPP] (reciprocal of varying 
concentrations of MVAPP) (Fig. 3.5b) or 1/[MgATP] (reciprocal of varying 
concentrations of MgATP)(Fig. 3.5d). The data were best represented by a sequential bi-
substrate model using the general equation for a bi-substrate enzyme catalysis system 
(Equation 3.5). The patterns in Figure 3.5b and Figure 3.5d show that the kinetic curves 
in the double reciprocal plots converge to the x-axis. We could then confirm the enzyme 
mechanism of MDDEF belongs to a sequential bi-substrate mechanism, but not a ping-
pong mechanism or a rapid-equilibrium sequential ordered mechanism. From the curve 
fitting, we could then obtain kinetic parameters: Vmax = 16.1 ± 0.3 (mole/min/mg), kcat = 
9.8 ± 0.2 (s
-1
), KmMVAPP = 39.7 ± 2.8 (M), KmMgATP = 166 ± 12 (M) (Table 3.2). We 





Figure 3.5 Kinetic analysis of MDDEF. (a) A set of kinetic data at varying 
concentrations of MVAPP and several fixed concentrations of MgATP ((●)50, (○)100, 
(▼)200, (▽)400, (■)600, (□)800 and (◆)1000 M) is represented by a Michaelis-
Menten plot. (b) The same data set from (a) is represented by a Lineweaver-Burk plot. (c) 
The same data set at varying concentrations of MgATP and several fixed concentrations 
of MVAPP ((●) 10, (○) 15, (▼) 25, (▽) 50, (■) 100, (□)150, (◆) 200 and (◇) 300 M) 
is represented by a Michaelis-Menten plot. (d)  The same data set from (c) is represented 
by a Lineweaver-Burk plot. Kinetic data are represented by Equation 3.5 used for a 
sequential bi-substrate model. Each data point represents independent triplicate results 







 In the literature, either a product or substrate analogue has been utilized for 
determining the substrate binding order of a given enzyme if it has more than one 
substrate. To determine the substrate binding mechanism of MDDEF, we considered 
whether to use either MVAPP analogues (such as DPGP or FMVAPP) (Fig. 3.6) or ATP 




Figure 3.6 MVAPP and its analogues. DPGP: diphosphoglycolyl proline; MVAPP: 





Figure 3.7 ATP and its analogues. ATP: adenosine triphosphate; AMPPCP: 
beta,gamma-Methylene ATP; AMPPNP: gamma-Imino-ATP; ATPS: gamma-Thio-ATP. 
The differences between ATP and its analogues are emphasized and shown in red. 
 
 In the literature, MVAPP was identified as the first substrate based on the kinetic 
study in MDD from chicken
60
 and the structural study in MDD from Staphylococcus 
epidermidis
59
. We hypothesized that if MVAPP were the first substrate followed by the 
ATP binding, we would need to use ATP analogues as dead-end inhibitors to obtain the 
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unique inhibitory patterns; to use MVAPP analogues would not provide solid results for 
us to differentiate an ordered binding mechanism from a random binding mechanism 
(Table 3.1). AMPPCP and AMPPNP are two ATP analogues commonly used in kinase 
studies. The difference between these two analogues and ATP is the replacement of the 
bridging oxygen between the - and -phosphate of ATP to either the CH2 group for 
AMPPCP or the NH group for AMPPNP (Fig. 3.7). It is known that AMPPCP and 
AMPPNP are weak inhibitors for MDD (Ki > 1mM)
72
, showing these two molecules are 
not suitable to be utilized in the inhibitory assays. Instead, ATPS (Fig. 3.7) has been 
shown to inhibit the enzymatic activity of MDD from chicken with a Ki value of about 
200 M
72
. Although ATPS can be an alternative substrate for some kinases
88
, it is fairly 
stable in our reaction system (suggested from our ITC experiments in the following 
chapter). Thus we could consider it as a dead-end inhibitor against MDDEF in this study.  
 According to Table 3.1, we would need to perform two sets of experiments with 
the addition of varying concentrations of ATPS in the reactions to determine the detailed 
substrate binding mechanism of MDDEF. The first set of experiments was performed at a 
constant MVAPP concentration of 40 M (about the KmMVAPP value: 39.7 M), and 
varying concentrations of MgATP (100, 150, 200, 400 M) and ATPS (0, 100, 200, 400 
M). Under this condition, the kinetic data set best fit a competitive inhibition model as 
described by Equation 3.6, where Vmax is the maximum velocity; [B] is the varying 
concentrations of ATP; KB is KmMgATP; KiA is KdMVAPP; KA is KmMVAPP; KiA/KA is 0.8 
which was derived from the general equation describe above; [I] is the varying 
concentrations of ATPS, and Ki is KiATPS. The kinetic data from the inhibitory assays 
were represented by a Mechaelis-Menten plot (Fig. 3.8a) and a Lineweaver-Burk plot 
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(Fig. 3.8b) and the inhibition pattern in this case belongs to a competitive inhibition 
pattern. The values of Vmax, KmMgATP and KiATPS were derived from Equation 3.6 and are 






 The second set of experiments was performed at a constant MgATP concentration 
of 200 M (about the KmMgATP value: 166 M), and varying concentrations of MVAPP 
(10, 20, 40, 80 M) and ATPS (0, 100, 200, 400 M). Each data point represents 
independent triplicate results and the error bar for each point indicates standard 
deviations. The data set was best represented by an uncompetitive inhibition model using 
Equation 3.7, where Vmax is the maximum velocity; [I] is the varying concentrations of 
ATPS, and Ki is KiATPS; KiA is KdMVAPP and KA is KmMVAPP; KiA/KA is 0.8 which was 
derived from the general equation describe above; [A] is the varying concentrations of 
MVAPP. The kinetic data from the inhibitory assays were represented by a Mechaelis-
Menten plot (Fig. 3.8c) and a Lineweaver-Burk plot (Fig. 3.8d) and the inhibition pattern 
in this case belongs to a competitive inhibition pattern. The values of Vmax, KmMVAPP, and 










Figure 3.8 Inhibitory assays of MDDEF. (a) Different fixed concentrations of ATPS 
((●) 0, (○) 100, (▼) 200 or (▽) 400 M) were added to the reactions at a fixed 
concentration of MVAPP (40 M) and varying concentrations of MgATP (100, 150, 200 
or 400 M). The set of inhibitory data is represented by a Michaelis-Menten plot. (b) The 
same set of data from (a) is represented by a Lineweaver-Burk plot. (c) Different fixed 
concentrations of ATPS ((●) 0, (○) 100, (▼) 200 and (▽) 400 M) were added to the 
reactions at a fixed concentration of MgATP (200 M) and varying concentrations of 
MVAPP (10, 20, 40 and 80 M). The set of inhibitory data is represented by a Michaelis-
Menten plot. (d) The same set of data from (c) is represented by a Lineweaver-Burk plot. 
(a) and (b) are represented by a competitive inhibition model; (c) and (d) are represented 
by an uncompetitive inhibition model. The means and the standard deviation of each data 
point were obtained from a triplicate test. Each data point represents independent 
triplicate results and the error bar for each point indicates standard deviations 
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 We have performed classical enzymatic reactions at varying concentrations of 
MgATP and MVAPP. The initial kinetic data for MDDEF best fit a sequential bi-substrate 
mechanism. Two sets of data from the inhibitory assays using the second substrate 
analogue, ATPS, were also in agreement with an ordered bi-substrate mechanism. At a 
fixed concentration of the first substrate, MVAPP, we observed a competitive inhibition 
pattern by varying the concentrations of MgATP and ATPS in the reactions; at a fixed 
concentration of the second substrate, MgATP, we observed an uncompetitive inhibition 
pattern by varying the concentrations of MVAPP and ATPS in the reactions. From the 
observation of inhibitory results, we therefore suggest that MDDEF binds to its two 
substrates, MVAPP and MgATP, in an ordered fashion with MVAPP binding first, and 


























16.1 ± 0.3 0.75 ± 0.02 9.8 ± 0.2 39.7 ± 2.8 166 ± 12 - Mg
2+
  
20.4 ± 0.8 0.94 ± 0.04 12.4 ± 0.6 42.6 ± 3.4 - 173 ± 16 Mg
2+
 Uncompetitive 




The means and the standard deviation of each data point were obtained from a triplicate test (Means 






 In the literature, there are two MVAPP analogues, 6-fluoromevalonate 5-
diphosphate (FMVAPP) and diphosphoglycolyl proline (DPGP), that compete the 
binding of MVAPP and show inhibitory potency against MDD from humans (KiFMVAPP = 
0.062 M, KiDPGP = 2.3 M)
69
 and Staphylococcus epidermidis (KiFMVAPP = 0.049 M, 
KiDPGP = 4 M)
67
. It has been also suggested that these two compounds can effectively 
inhibit the MDD family of proteins due to the conserved features of MVAPP binding 
pocket in the active site across MDDs. However, in this study, MVAPP analogues could 
not be utilized for determining the substrate binding order because the derived inhibitory 
patterns would not be conclusive for differentiating whether the binding mechanism of 
MDDEF belongs to a sequential ordered or random bi-substrate mechanism (Table 3.1). 
The second substrate analogue can be utilized since the derived inhibitory patterns are 
unique. At a constant concentration of MVAPP and varying concentrations of MgATP 
and ATPS, the results show a competitive inhibition pattern since ATPS can bind to the 
ATP binding pocket
59
 and compete with ATP. At a fixed concentration of MgATP and 
varying concentrations of MVAPP and ATPS, the results best fit an uncompetitive 
inhibition model. The feature of uncompetitive inhibition is that an inhibitor can enhance 
the substrate binding and simultaneously reduce the enzymatic rate. From structural 
points of view, the ATP binding pocket of MDD locates right above the MVAPP binding 
pocket, suggesting the binding of ATPS may block the dissociation of MVAPP from 
MDDEF, and thus the inhibitory pattern shows uncompetitive and decreasing apparent 
KmMVAPP when increasing ATPS concentrations (Fig. 3.8d).  
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 Sequential ordered bi-substrate mechanisms can be further classified into rapid-
equilibrium, steady-state and Theorell-Chance mechanisms. Our kinetic studies (Fig. 3.5) 
shows the reaction is not a rapid equilibrium ordered mechanism, meaning the chemical 
steps in the MDDEF reaction are not rate-limiting if compared with the substrate binding 
and product release. However, the inhibition patterns derived from our inhibitory assays 
would not allow us to determine if the reaction is either a steady-state or a Theorell-
Chance mechanism. Although the first priority in this study is to determine the substrate 
binding order of MDDEF, in the future, we will need to perform enzymatic reactions using 
alternative substrates or product inhibition strategies at both saturated and unsaturated 
concentrations of MVAPP and MgATP
89
 to comprehensively investigate the overall 
enzyme mechanism of MDDEF. 
 From the kinetic study on MDDEF, MVAPP is suggested to be the first substrate 
in the reaction. Our first crystal structure of MDDEF in complex with ATP showed that in 
the absence of MVAPP, ATP binds the ATP binding pocket in an unusual configuration 
(Fig. 2.2d) and the phosphate binding loop does not bend down to interact with the ATP 
molecule (Fig. 2.2c). These results suggest MVAPP has to bind to the active site in the 
first step of the reaction, and also imply the binding of MVAPP may cause 
conformational changes that re-shape the ATP molecule and the phosphate binding loop 
to their catalytically favored configuration. An ATP molecule in a favored configuration 
in the active site may be a stronger binder than one in an unusual configuration. In other 
words, the binding of MVAPP might induce conformational changes which facilitate the 
binding of ATP.  
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CHAPTER 4. THERMODYNAMIC STUDIES ON MDDEF BY ISOTHERMAL 
TITRATION CALORIMETRY SUGGEST A SUBSTRATE-INDUCED 
SUBSTRATE BINDING MECHANISM FOR MDDEF  
4.1 Chapter Summary 
 The structural information from MDDEF-ATP and the MDDEF enzyme kinetics 
results suggest that the pre-binding of MVAPP could induce conformational 
rearrangements of MDDEF and thus enhance the ATP binding. To further test this, we 
employed thermodynamic approaches and utilized isothermal titration calorimetry (ITC) 
to determine the dissociation constants of first substrate, MVAPP, second substrate, 
MgATP, and ATP analogues, ATPS and AMPPCP. Our results were in agreement with 
our proposed model, in which the binding of ATPS was enhanced by the prerequisite 
binding of MVAPP to MDDEF, suggesting the binding of MVAPP would accommodate 
the ATP molecule in its catalytically favored position for the following chemical steps in 
the reaction. 
4.2 Introduction 
 Our experimental evidence suggests that the binding of MVAPP will affect ATP 
binding. From our kinetic study, the enzyme mechanism belongs to a sequential ordered 
bi-substrate mechanism with MVAPP binding first; the crystal structure of MDDEF-ATP 
showed an unusual ATP configuration. We would then hypothesize that the binding 
affinity of ATP to MDDEF might be enhanced by the prerequisite binding of MVAPP. To 
54 
 
better understand these binding events, we introduced thermodynamic approaches into 
our research. So far, there are no substrate analogues exhibiting distinguishing changes in 
absorbance or fluorescence signals upon binding to MDDEF. Therefore, isothermal 
titration calorimetry (ITC) was employed in this study to measure thermodynamic 




 The main concept of the ITC technique is to detect heat changes in a system when 
macromolecule-ligand binding events take place. In the design of ITC, the temperature of 
the reference cell and the sample cell are controlled and monitored. The reference cell is 
filled with either buffer or water, and the sample cell is filled with either macromolecules 
or ligands depending on the experimental design. The injection syringe is filled with the 
titrant of interest which is then injected into the sample cell (Fig. 4.1a). The two binding 
partners in the sample cell will form a complex either resulting in heat absorption 
(endothermic reaction) or release (exothermic reaction), and the heat difference between 
the reference cell and the sample cell will be monitored overtime (Fig. 4.1b). Because the 
temperature has been set to be the same in these two cells, the ITC instrument will adjust 
the power input to the sample cell to maintain the temperature. Once the data have been 
collected (Fig. 4.1c), the heat changes per injection (area under or above the baseline) 
will be calculated to generate a thermogram, in which the heat of injection in kcal/mole is 
plotted as a function of molar ratio of ligand/macromolecule in the sample cell (Fig. 
4.1d). After curve fitting, the thermodynamic parameters, stoichiometry (n), binding 
constant (Ka) and enthalpy (H) can be derived. The Gibbs free energy (G) can then be 




Figure 4.1 Background of ITC. (a) A cartoon figure showing the ITC instrument 
containing a reference cell, and a sample cell, and a syringe with a titrant (yellow) which 
can be injected into the sample cell for the following titrations. (b) An ongoing 
thermogram (black line) with illustrations of macromolecule-ligand binding 
(macromolecules in blue and ligands in red) at the top. The heat of the binding reaction is 
released (exothermic). (c) A complete thermogram (black line) with the calculated 
baseline (red line). (d) The ITC data were processed and the heat changes were plotted as 
a function of the molar ration of ligand to macromolecule. The binding constant (Ka), 
stoichiometry (n) and enthalpy (H) can be derived from curve fitting. Ka is related to the 
slope (red dash). 
 In order to test if the binding of MVAPP can enhance the strength of ATP binding, 
we want to determine the dissociation constant Kd (1/Ka). This can be achieved using 
either a catalytically dead mutant of MDDEF or stable substrate analogues (FMVAPP, 
ATPS, etc.). In the literature, it has been suggested that Asp283 of MDDSE in the active 
site serves as a catalytic residue for de-protonizing the 3’-OH group of MVAPP, followed 
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by the phosphoryl transfer of ATP -phosphate and spontaneous decarboxylation to yield 
isopentenyl diphosphate (IPP) (Fig. 4.2)
91
.  
 Although the dead mutant of MDDSE (D283A) has non-detectable enzymatic 
activity, we found that this D-to-A mutant would not be suitable for thermodynamic study 
and the determination of KdATP values because MVAPP appears to bind in different ways 
in the wild type and the mutant of MDDSE. Two structures, MDDSE in complex with 
FMVAPP and ATPS (MDDSE-FMVAPP-ATPS, PDB: 4DPT) and a D283A mutant of 
MDDSE in complex with MVAPP and ATPS (D283A-MVAPP-ATPS, PDB: 4DPW), 
were superimposed (Fig. 4.3a) with an r.m.s.d. value of 0.47Å. However in D283A-
FMVAPP-ATPS, the conformation of MVAPP is different from FMVAPP in MDDSE-
FMVAPP-ATPS and it no longer interacts with Arg144, if compared with FMVAPP in 
MDDSE-FMVAPP-ATPS (Fig. 4.3b). This suggests that Asp283 may also play a role in 
the binding of MVAPP which could then change its effect on ATP binding, since the 
conformation of phosphate tails of ATPS in these two structures are also different (Fig. 
4.2b). Therefore, the D-to-A mutant may not be suitable to determine Kd values of 
ligands/substrates. In this situation, we will need to use wild type proteins and inactive 
analogues for mimicking the binding event in catalysis. From our enzymology study, 
ATPS can inhibit MDDEF enzymatic activity, so it is expected that ATPS can also bind 
MDDEF. Here we will test if MVAPP assists in ATPS binding i.e. we would like to 











Figure 4.3 Superimposition of two tertiary crystal structures of MDD from S. 
epidermidis (4DPT) and its mutant, D283A (4DPW). (a) The overlay of the two 
tertiary structures of the wild type MDDEF (pink) and the D283A mutant (green) in 
complex with their ligands. The r.m.s. deviation of these two structures (excluding the 
ligands) was calculated to be 0.47 Å. (b) The active-site ligand architecture in these two 
structures. A283 and MVAPP from the D283A mutant are depicted and colored in green; 
D283 and FMVAPP in pink are from wild type MDDSE; common features, R144 and 




4.3 Materials and Methods 
4.3.1 Isothermal titration calorimetry (ITC) experiments 
 The preparation of TEV-treated MDDEF was described in the previous chapter. 
The protein solution was dialyzed against buffer which is the same as used in the 
enzymatic reactions described previously (100 mM HEPES, pH 7, 100 mM KCl and 10 
mM MgCl2). All the buffer solutions in ITC experiments were filtered through 0.45 m 
filter and degassed for 1 hour at room temperature. The protein concentration was 
adjusted to 100 M (260 l). Each ligand (MVAPP, ATP, AMPPCP and ATPS) was 
prepared in the same dialysis buffer to avoid buffer mismatch. The concentration of each 
titrant was optimized in different experiments based on the experimental designs 
simulated using the MICROCAL ORIGIN 7.0 software package, and the final concentration of 
each ligand was adjusted to 2 or 3 mM. The ITC instrument, MicroCal iTC200, was 
employed for isothermal titrations in this study and the reference cell was filled with 
ddH2O containing 0.01% sodium azide. The experimental temperature was set at 25℃. 
Each experimental profile composed of the addition of an initial aliquot of 0.4 l, 
followed by 22 aliquots of 1.8 l of the substrate or ligand solution. The time interval 
between two consecutive injections was 180 seconds. The data were further processed 
with NITPIC
92
 and analyzed using an one-site model in SEDPHAT
93
. Figures were 





4.3.2 Analysis of ITC data 
 For a simple 1-to-1 binding event, the thermograms were obtained after titrations 
and the stoichiometry n, enthalpy H and the binding constant Ka can be derived from the 
curve fitting to the simple 1-to-1 binding mode (Equation 4.1) by Marquardt nonlinear 































In Equation 4.1, n represents the stoichiometry number, H enthalpy, Ka the binding 
constant, [M]t the concentration of macromolecules in the sample cell, and [L]t the 
concentration of a certain ligand in the sample cell. In each injection, the heat changes 
(Qi = Qi – Qi-1) from new complex formation were measured. After curve fitting, Ka (1/ 
Kd), n and H can be derived. Another thermodynamic parameter, entropy (S) can be 
obtained from the Gibbs free energy (G) of binding shown in Equation 4.2, where G is 
















 For designing ITC experiments, the ligand concentration in the syringe would be 
about 10-fold greater than the concentration of macromolecules in the sample cell, so that 
the molar ratio of ligand/macromolecule in the x-axis of a thermogram will end up at 2 
for a 1-to-1 binding mode and the thermogram will ideally look like a sigmoid curve. In 
Equation 4.1, the term “nKa[M]t” is referred to the “C” value, which is an indication for 
experimental designs. In general, the C value is suggested to be in a range between 10 to 
1000, in which H and Kd (1/Ka) can be accurately obtained. A lower C value (C < 10) 
will result in a flat curve, which may not be useful for deriving thermodynamic 
parameters; and a higher C value (C > 3000) will result in an inaccurate Kd (1/Ka) value 
after curve fitting (Fig. 4.4).  
 In this study, the binding of ATP or ATP analogues to MDDEF was determined 
weak (200 to 300 M, C = 0.2 to 0.3), and the heat changes upon binding were not huge. 
Instead of increasing the protein concentration in the sample cell to obtain a better 
titration experiment, we increased the ligand concentration in the syringe to increase the 
heat changes per injection so that we could obtain more accurate thermodynamic 






Figure 4.4 Simulation of ITC thermograms. H is set at 10, and the binding is one-to-
one. The concentration of macromolecules is 100 M; the concentration of ligands is set 
at 1 mM. The “C” value is equal to n*Ka*[M]t described above. Heat changes are plotted 
as a function of the molar ratio of ligand to macromolecule. 
 We have performed several ITC experiments for determine the Kd values of 
substrates or ligands (MVAPP, ATP and ATP analogues, AMPPCP and ATPS). The raw 
data for titrations of wild type MDDEF are shown in Figure 4.5. All the derived 
thermodynamic parameters, Kd (1/Ka), are listed in Table 4.1. First, we have performed 
experiments to determine the Kd values between MDDEF and each substrate/analogue, 
MVAPP, ATP, AMPPCP or ATPS. The KdMVAPP value is 20.4 ± 9.3 M; the KdATP value 
is 288 ± 36 M; the KdATPS value is 215 ± 8 M (Fig. 4.5a, b, c and Table 4.1 row a, b, 
c). Second, we performed ITC experiments to determine the KdATPS values under the 
condition where MDDEF was pre-incubated with MVAPP. To assure that the MVAPP 
binding pocket of MDDEF was nearly fully-occupied (more than 90%) with MVAPP, we 
used a MVAPP concentration of 1 mM. According to the KdMVAPP value (20.4 ± 9.3 M) 
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derived from the previous ITC experiment, the concentration of the MDDEF-MVAPP 
complex ([MDDEF-MVAPP]complex, represented as 𝑥  in Equation 4.3) can be calculated 
based on the total concentration of MDDEF ([MDDEF]total) and the total concentration of 




([MDDEF]total − 𝑥)([MVAPP]total − 𝑥)
[MDDEF-MVAPP]complex
 




 In our ITC experiment, [MVAPP]total was set at 1 mM, which was ten-fold greater 
than [MDDEF]total (100 M). Using Equation 4.3, the [MDDEF-MVAPP]complex was 
approximately calculated to be 97.8 M, meaning MDDEF was about 97.8%-saturated 
with MVAPP in the system. Under these conditions, the Kd value between ATPS and 
MDDEF-MVAPP was determined to be 25.4 ± 5.5 M (Fig. 4.5d and Table 4.1, row d), 
which was ten-fold less than the Kd value between ATPS and MDDEF alone (Fig. 4.5c 
and Table 4.1, row c), supporting our proposed model in which the pre-binding of 






Figure 4.5 The original titration curves from ITC experiments with MDDEF. (a) 
MDDEF (100 M) titrated with MVAPP (2 mM). (b) MDDEF titrated with ATP (3 mM). 
(c) MDDEF titrated with ATPS (3 mM). (d) MDDEF pre-incubated with MVAPP (1 mM) 
and then titrated with ATPS (2 mM). The protein concentration is adjusted to 100 M 
and all the protein and titrants are dissolved in the buffer containing 100 mM HEPES, pH 






Table 4.1 Thermodynamic parameters* 











a MDDEF (100M) 
MVAPP 
(2 mM) 
20.4 ± 9.3 -6.5 ± 0.3 -0.7 ± 0.1 5.8 ± 0.2 19.5 ± 0.5 
b MDDEF (100 M) 
ATP 
(3 mM) 
288 ± 36 -4.8 ± 0.1 -3.8 ± 0.5 1.0 ± 0.3 3.5 ± 1.0 
c MDDEF (100 M) 
ATPγS 
(3 mM) 
215 ± 8 -5.00 ± 0.02 -6.4 ± 0.3 -1.4 ± 0.2 -4.7 ± 0.6 
d MDDEF (100 M) +   
MVAPP (1 mM) 
ATPγS 
(2 mM) 
25.4 ± 5.5 -6.3 ± 0.1 -4.8 ± 1.1 1.5 ± 0.6 5.0 ± 2.1 
*Titration experiments were done at 25℃.  





) and the standard deviation of 
ΔG () is calculated from the equation: σ =  √ln (1 +  
𝑣
𝑚2
), where m is the mean of the association 
constant (Ka) and v is the variance of Ka derived from each ITC experiment. 
# The mean of TS () is derived from the difference between the means of G (1) and H ( 2) and 








 , where 1 is the 




 We assumed that MVAPP could also induce changes needed for enhanced ATP 
binding to MDDEF. And the thermodynamic results are in agreement with our previous 
observations in enzyme kinetics and the crystal structure of MDDEF-ATP. In addition to 
the examination of changes of KdATPS in the presence of excess amounts of MVAPP in 
the solution, we also tested whether this enhanced binding event occurs using AMPPCP. 
The KdAMPPCP value was 271 ± 43 M (Fig. 4.6a and Table 4.2 row a); however, in the 
presence of MVAPP, we could not detect heat changes and so could not obtain the 
thermodynamic parameters in this case (Fig. 4.6b and Table 4.2 row b). When MDDEF 
was pre-incubated with excess amounts of AMPPCP (10-fold, MDDEF-AMPPCP 
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complex formation rate: 77.4%) and then the mixture was titrated with MVAPP (Fig. 4.6c 
and Table 4.2 row c), the KdMVAPP value in this case is 18.7 ± 7.4 M, which is a similar 
value as from the MDDEF-MVAPP titration (Fig. 4.5a and Table 4.1 row a); we have also 
a preliminary test on ATPS. MDDEF was pre-incubated with excess amounts of ATPS 
(10-fold, MDDEF-ATPS complex formation rate: 81.1%) and then the mixture was 
titrated with MVAPP (Fig. 4.6d and Table 4.2 row d). The thermogram shows an unusual 
two-process binding event and the titration ended after the 6
th
 injection, suggesting a tight 
binding event occurs. KdMVAPP was roughly determined to be 76nM (data not shown). 
Although there are no other experimental results to explain the two-process binding, a 
quick saturation after the 6
th
 injection indicates that MVAPP binds MDDEF-ATPS much 
tighter than MVAPP binds MDDEF alone (Fig. 4.5a and Table 4.1 row a). It also implies 
that AMPPCP might not “lock” MVAPP in the active site and thus not affect the release 





Figure 4.6 The original titration curves from ITC experiments with MDDEF. (a) 
MDDEF (100 M) titrated with AMPPCP (3 mM). (b) MDDEF pre-incubated with 
MVAPP (1 mM) and then titrated with AMPPCP (5 mM). (c) MDDEF pre-incubated with 
AMPPCP (1 mM) and then titrated with MVAPP (2 mM). (d) MDDEF pre-incubated with 
ATPS (1 mM) and then titrated with MVAPP (2 mM). The protein concentration is 
adjusted to 100 M and all the protein and titrants are dissolved in the buffer containing 








Table 4.2 Thermodynamic parameters* 











a MDDEF (100 M) 
AMPPCP 
 (3 mM) 
271 ± 43 
-4.87 ± 
0.09 
-3.20 ± 0.50 1.67 ± 0.36 5.61 ± 1.21 
b MDDEF (100 M) +   
MVAPP (1 mM) 
AMPPCP 
 (5 mM) 
NDB NDB NDB NDB NDB 
c MDDEF (100 M) +   
AMPPCP (1 mM) 
MVAPP  
(2 mM) 
18.7 ± 7.4 
-6.50 ± 
0.23 
0.91 ± 0.18 7.41 ± 0.20 24.88 ± 0.69 
d MDDEF (100 M) +   





- - - - 
*Titration experiments were done at 25℃.  





) and the standard deviation 
of ΔG () is calculated from the equation: σ =  √ln (1 +  
𝑣
𝑚2
), where m is the mean of the association 
constant (Ka) and v is the variance of Ka derived from each ITC experiment. 
# The mean of TS () is derived from the difference between the means of G (1) and H ( 2) 
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CHAPTER 5. CRYSTAL STRUCTURES OF THE APO AND LIGAND-BOUND 
FORMS OF MDDEF PROVIDE SNAPSHOTS OF THE MDD ENZYMATIC 
REACTION 
5.1 Chapter Summary 
 In this chapter, we will discuss the conformational changes of MDDEF upon 
substrate binding in an ordered manner. From the previous enzymology study, MVAPP 
was determined to be the first substrate, and MVAPP has also been suggested to induce 
structural rearrangements for the accommodation of the second substrate, MgATP, based 
on the thermodynamic evidence. The previous condition used for MDDEF-ATP 
crystallization was not suitable for growing the crystals of apo-MDDEF, so we started 
over with crystallization screening and obtained a stable condition for constantly 
producing apo-form MDDEF crystals. We exchanged the crystallization buffer with the 
soaking buffer for the ligand soaking experiments. By doing that, we were able to obtain 




) for the 





). From those structures, we 
observed intriguing conformational changes in five regions of MDDEF: the phosphate 
binding loop, the 10-4 loop, Helix 1, 2 and 4. We have also confirmed that there 
are two metal binding sites during catalysis by detecting the anomalous signals from 









). These new findings allow us to propose detailed models for 
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elucidating the MDDEF substrate binding mechanism and enzyme catalysis. From the 
substrate binding model, we identified possible drug targeting areas for the future specific 
drug design. 
5.2 Introduction 
 In 2012, the substrate binding mechanism of the MDD family of proteins was 
proposed based on the structural observation from the apo-enzyme (4DPX) and ligand-
bound structure of MDDSE (4DU7: MDDSE-MVAPP; 4DPT: MDDSE-FMVAPP-ATPS)  
in which only the phosphate binding loop was identified to be involved in substrate 
accommodation
59
. However, the 10-4 loop (183-192) near the active site was un-
determined due to poor electron density maps around this area. In this loop region, one 
conserved lysine residue (Lys189 in MDDSE and Lys187 in MDDEF) has been suggested 
to be pivotal for the enzyme activity, yet its role is unrevealed. Metal ions, specifically 
Mg
2+
, have been known to be involved in catalysis
60
; however, the metal binding site(s) 
in the MDD structures were also not defined. These observations imply that the published 
structural models are still insufficient for elucidating substrate binding and catalytic 
mechanisms of the MDD family of proteins and that the ligand architectures in the 
complex structures may be still questionable. 
 Another problem with obtaining ligand-bound forms of MDD is the strong 
tendency of this protein to bind sulfate/phosphate. MDD from Legionella pneumophilia 
(3LTO), MDD from Mus musculus (3F0N), and MDD from Homo sapiens (3D4J)
69
 have 
been crystallized under conditions containing sulfate or phosphate ions. In all three cases, 
sulfate or phosphate has been shown to occupy a part of the MVAPP binding site and thus 
71 
 
compete with substrate binding. Higher concentrations (> 200 mM) of these two ions 
hamper the binding of MVAPP and thus ligand soaking experiments failed in the case of 
MDD from Homo sapiens (3D4J)
69
. We initially obtained stable crystals under the 
condition containing 1.45M of ammonium sulfate and in our preliminary results ligands 
could not compete with sulfate binding in the active site (data not shown). Here we also 
describe experimental strategies to overcome the sulfate/phosphate problem and still 
maintain protein crystals in the same space group, P21212, so that several substrate 
complex structures of MDDEF structures can be compared. 
5.3 Materials and Methods 
5.3.1 Protein crystallization, crystal soaking and cryo-protection procedures 
 A stable condition (1.6 M ammonium sulfate, 50 mM sodium acetate, pH 4.6) for 
growing crystals was obtained and optimized from a commercialized crystallization 
screening kit (Qiagen, Class II, condition A2: 0.1M sodium acetate, pH 4.5, 2M 
ammonium sulfate). Protein solution (8 to 9 mg/ml) was mixed with the reservoir 
solution at an 1:1 ratio and equilibrated by vapor diffusion of sitting drops at 20 ℃ for 
two days. In a 96-well plate, there were about 20 wells containing single cuboid crystals 
with a size of 0.2 to 0.3 mm. To perform buffer exchange for ligand soaking experiments, 
the crystallization buffer surrounding protein crystals was replaced by soaking buffer (26 
% PEG3350, 5 mM MgCl2, 50 mM sodium acetate, pH 4.6) and crystals were then 
equilibrated in soaking buffer for 10 minutes. Each ligand was dissolved in soaking 
buffer to a final concentration of 2 mM and a small amount of ligand solution (0.12 to 
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0.15 l) was added into the drop for a one-day soaking procedure. For cryo-protection, 
dehydration buffer (30 % PEG 3350, 15 % PEG400, 50 mM sodium acetate, pH 4.6) was 
placed into the bottom well of each individual chamber in order to increase the PEG3350 
concentration in the sitting drop. Crystals of MDDEF soaked with ligands and metal ions 












) were obtained and frozen and 
stored in liquid nitrogen after the dehydration process.  
 
5.3.2 Data collection, structure determination, refinement analysis, refinement 
statistics, and substructure determination 







 were collected at the 23-ID-D beamline at 
Advanced Photon Source (APS) at Argonne National Laboratory in Chicago. Diffraction 





) were collected on the home-source X-ray diffraction equipment. The 
phases for determining crystal structures of MDDEF with ligands were solved by 
molecular replacement in Phenix.phaser
76
 using the protein structure of MDDEF-ATP in 









, and AMPPCP) were obtained from phenix.eLBOW
76
, and were 
manually fitted into difference maps (Fo-Fc) in Coot
81
, respectively. Structure refinement 
for each crystal structure was performed in phenix.refine
76
 and the refinement and 
structure statistics for each individual structure were summarized in Table 5.1 The 
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 were calculated using 
phenix.composite_omit_map
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5.4.1 Soaking experiments for obtaining ligand-bound crystal structures of 
MDDEF 
 From our previous experiments, we know that MVAPP is the first substrate of 
MDDEF, and that the binding of MVAPP appears to facilitate the binding of the second 
substrate, MgATP. These results implied the first substrate binding may trigger structural 
rearrangements in MDDEF. To test this, we would need the aid of crystal structures of 
MDDEF without or with ligands to identify differences from those structures. The 
crystallization condition for growing MDDEF-ATP crystals described in Chapter 2 was 
not able to produce crystals of apoenzyme or ligand-bound structures of MDDEF. After 
crystallization screening against six commercial trays (class I and II, and JCSG I, II, III 
and IV from Qiagen) and condition optimization, we were able to obtain a stable 
condition for growing apo-MDDEF crystals, and its space group was determined as 
P21212, which is the same as the space group in MDDEF-ATP. Because of the high 
concentration of (NH4)2SO4 at 1.6 M in the crystallization solution, MVAPP was not able 
to bind to the enzyme using standard co-crystallization or soaking techniques. This 
problem had also been discussed in the case of MDD from Homo sapiens
69
. In the 
literature, co-crystallization for obtaining ligand-bound protein crystals is a frequently 
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used option and had been used in growing tertiary complex crystals for MDD from S. 
epidermidis
59
; however, different space groups and crystal packing may affect the 
structural architecture at certain regions of interest. To avoid those potential artifacts, we 
chose to use buffer exchange to wash away excess amounts of ammonium sulfate before 
soaking experiments so that MVAPP can bind the active site of MDDEF. First we needed 
to survey different buffer components that would keep the MDDEF crystals intact and 
preserve their diffraction. From our previous findings, MDDEF-ATP crystals grew under 
the condition containing 25 % PEG3350, implying that under this condition, MDDEF 
protein crystals might not dissolve. Thus, we prepared soaking buffer containing 27% 
PEG3350 and 50 mM sodium acetate, pH 4.6, and replaced the original buffer with this 
soaking buffer. Although crystals cracked a little in the beginning of the buffer exchange 
procedures, the “wounds” healed after a few minutes of equilibrium, and the buffer-
exchanged MDDEF crystals retained their original shape without dissolving. Tests of 
diffraction from these crystals on the home source X-rays displayed resolution that 
extended at least to 2.4 Å  using I/ > 2 in the outer most shell as a criterion), and those 
protein crystals maintained the same space group, P21212. 
 After three to four times of buffer exchange, MDDEF crystals were ready for the 
soaking experiments. For preparing a MDDEF-MVAPP crystal, 0.12 l of 2 mM of 
MVAPP in the soaking buffer were added into a 2-l drop containing a MDDEF crystal. It 
was noticed that more than 0.15 l of MVAPP caused severe crystal cracking and 
produced multiple crystals by breaking up one crystal. In order to cryo-protect these 
crystals, we tried to add cryo-protectant directly into the top well containing MDDEF 
crystals; however, this method caused severe crystal cracking.  
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 Our final procedure for cryo-protecting the buffer-exchanged MDDEF crystals 
(without or with ligand soaking) was to add 50 l of the dehydration buffer into the 
bottom well of the hanging drop chamber to condense the top well solution. After one 
day of equilibrium, the solution surrounding a MDDEF crystal would have cryo-protection 






crystals, one more step of ligand soaking was performed after the initial MDDEF-MVAPP 
soaking experiment was done. Using these techniques, we have obtained MDDEF crystal 





































Data collection*    
Space group P21212 P21212 P21212 
Cell dimensions    
   a, b, c (Å) 82.4, 97.9, 45.7 79.3, 97.5, 45.8 80.0, 97.0, 46.0 
 ()  90.0, 90.0, 90.0 90.0, 90.0, 90.0 90.0, 90.0, 90.0 
Resolution (Å) 33.4–1.8 (1.84–1.79) 50.0–1.7 (1.76–1.70) 30.0–2.1 (2.12–2.05) 
Rmeas (%) 6.6 (54.3) 5.4 (47.4) 4.6 (57.6) 
I / I 32.3 (3.1) 40.1 (4.1) 38.6 (2.5) 
Completeness (%) 99.2 (100.0) 99.5 (100.0) 96.6 (98.5) 
Redundancy 7.0 (6.9) 6.8 (6.8) 5.1 (4.9) 
CC1/2 (%) 92.6 93.1 84.6 
CC* (%) 98.1 98.2 95.7 
    
Refinement    
Resolution (Å) 33.4 – 1.8 30.8 – 1.7 25.6 – 2.1 
No. reflections in 
test/free R 
32861/1719 37860/1929 20979/1078 
Rwork / Rfree 19.7 / 22.6 16.4 / 18.9 18.1 / 21.4 
Estimated 
coordinate error (Å) 
0.17 0.14 0.21 
No. atoms    
    Protein 2607 2492 2528 
    Ligand/ion 10 18 50 
    Water 180 371 145 
B-factors    
    Protein 20.7 12.9 30.9 
    Ligand/ion 26.5 8.23 35.4 
    Water 25.4 24.1 32.9 
R.m.s. deviations    
    Bond lengths (Å) 0.006 0.008 0.007 
    Bond angles () 0.93 0.92 0.80 
Ramachandran Plot 
 
   
   Most Favored (%) 98.98 99.05 98.46 
   Allowed (%) 1.02 0.95 1.54 
   Outliers (%) 0 0 0 
*Structure determined from one crystal.  
*Values in parentheses are for highest-resolution shell. 
*Each single crystal was placed in the soaking buffer containing 26 % PEG3350, 5 mM MgCl2, 50 mM 



















Data collection*   
Space group P21212 P21212 
Cell dimensions   
   a, b, c (Å) 79.8, 98.8, 45.7 80.0, 98.1, 45.9 
 ()  90.0, 90.0, 90.0 90.0, 90.0, 90.0 
Resolution (Å) 25.0–2.4 (2.43– 2.35) 50.0–2.0 (2.02–1.95) 
Rmeas (%) 6.6 (81.5) 5.9 (52.9) 
I / I 27.9 (2.1) 37.8 (3.5) 
Completeness (%) 100.0 (100.0) 99.2 (100.0) 
Redundancy 6.6 (6.3) 6.8 (6.7) 
CC1/2 (%) 70.8 91.7 
CC* (%) 91.0 97.8 
   
Refinement   
Resolution (Å) 23.6 – 2.34 31.0 – 1.95 
No. reflections in 
test/free R 
14216/759 25189/1291 




No. atoms   
    Protein 2539 2528 
    Ligand/ion 51 52 
    Water 105 219 
B-factors   
    Protein 33.8 22.9 
    Ligand/ion 27.4 18.1 
    Water 32.1 28.21 
R.m.s. deviations   
    Bond lengths (Å) 0.002 0.012 




    Most Favored (%) 97.85 97.85 
   Allowed (%) 2.15 2.15 
   Outliers (%) 0 0 
*Structure determined from one crystal.  
*Values in parentheses are for highest-resolution shell.  
*Each single crystal was placed in the soaking buffer containing 26 % PEG3350, 5 










 We have determined crystal structures of unbound and ligand-bound forms of 
MDDEF. In the apo form of MDDEF, two regions, the phosphate binding loop (97-104) 
and the 10-4 loop (183-190) cannot be determined due to poor electron density maps 
in these regions. After soaking protein crystals with MVAPP, we determined the overall 
structure of MDDEF-MVAPP (Fig. 5.1a), and surprisingly, we could determine the 
conformation of the 10-4 loop (Fig. 5.1a, black line) and the MVAPP molecule in the 
active site (Fig. 5.1b) based on the electron density maps. The binding pose of MVAPP in 
our structure was similar to what was found in the case of MDDSE in complex with 
FMVAPP and ATPS
59
. To show the binding of the second substrate, we prepared crystals 
of MDDEF soaked with MVAPP and AMPPCP. In this structure, we can determine both 
the 10-4 loop (Fig. 5.1c, black line) and the phosphate binding loop (Fig. 5.1c, red 
line) based on the electron density maps in these regions, and also observe the electron 
density of AMPPCP in the ATP binding pocket (Fig. 5.1d). In this structure, the 10-4 
loop and the phosphate binding loop do not interact with ligands in the active site, and the 
overall structure remained in an opened conformation. Finally, we prepared crystals of 
MDDEF soaked with MVAPP and ADPBeF3 as a model mimicking a pre-phosphoryl 
transfer state and determined this tertiary MDDEF crystal structure. In this structure, we 
can determine the 10-4 loop (Fig. 5.1e, black line), the phosphate binding loop (Fig. 
5.1e, red line), and ligands in the active site (Fig 5.1f). Intriguingly, only in this complex 
do these two loops bend toward the active site. For this transition state intermediate 
model complex, the overall structure was in a closed conformation.  
 In the structure with two bound substrates/analogues (MDDEF-MVAPP- 
AMPPCP-Mg
2+
), in addition to the electron density for MVAPP and AMPPCP, we 
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observed extra density between these two ligands. Since five oxygen atoms (one from 
MVAPP, three from AMPPCP and one from -OH of Ser106) were found to be 
surrounding the extra density within 2.8 Å, we hypothesized that this extra density 
belongs to a magnesium ion. In the structure of MDDEF-MVAPP-ADPBeF3-Mg
2+
, we 
also observed two extra densities in the active site besides MVAPP and ADPBeF3. One 
surrounded by six oxygen atoms (one from MVAPP, two from ADPBeF3, one from the -
OH of Ser106 and one from water) was found to be at a position similar to the extra 
density in MDDEF-MVAPP-AMPPCP-Mg
2+
, and another one was coordinated by five 
oxygen atoms (three from water and two from MVAPP) and one fluorine atom from 
BeF3
-
. This then suggested that these two extra electron density spheres were from two 



























Figure 5.1 Structural models of bound forms of MDDEF. (a) A cartoon model of the 
crystal structure of MDDEF-MVAPP with the MVAPP ligand shown as stick model. 
(b)The SA-ligand omit map (3) of MVAPP in MDDEF-MVAPP is depicted. Residues 
involved in substrate binding and the MVAPP model are shown in stick. (c) A cartoon 
model of the crystal structure of MDDEF-MVAPP-AMPPCP-Mg
2+
 with the MVAPP and 





 is depicted; S106 involved in 
metal chelating is shown in stick and one Mg
2+
 ion in green sphere. (e) A cartoon model 
of the crystal structure of MDDEF-MVAPP-ADPBeF3-Mg
2+
 and the ligands shown in 
stick and sphere. (f) The SA-omit map (2.5) of ligands (MVAPP, ADP, BeF3
-
 and two 
Mg
2+ 
ions) in MDDEF-MVAPP-AMPPCP- Mg
2+
 is depicted; S106 and 3 water molecules 
(in red sphere) involved in metal chelating are indicated; the catalytic residue, D282, is 























5.4.2 Cobalt replacement in enzymatic and crystallographic studies reveal two 
metal binding sites during MDDEF enzyme catalysis 
 In the active site of MDDEF-MVAPP-ADPBeF3-Mg
2+
, the two spherical densities 
between MVAPP and ADPBeF3 were suggested to belong to magnesium based on the 
octahedral coordination patterns. In the literature, cobalt has been shown to be an 
alternative metal for MDDEF catalysis
94
. Cobalt can absorb the CuK X-ray radiation 
available on a home source to produce detectable anomalous signals
95
. To confirm that 
MDDEF utilizes cobalt for the reaction, we measured the enzymatic activity and obtained 
the kinetic parameters (Vmax = 9.5 ± 0.3 mol/min/mg, KmMgATP = 188 ± 13 M, KmMVAPP 
= 39.3 ± 4.0 M) under the condition with cobalt replacement (Fig. 5.2a and b). With 
cobalt replacing magnesium, the value of Vmax was determined to be about 70% 
compared with the Vmax value under the normal condition with magnesium. This was 
similar to the result in the previous study
94
. Although cobalt can reduce the enzymatic 
activity of pyruvate kinase in the coupled reaction assay, this assay can measure the 
reaction velocity up to 85.4 ± 2.8 mol/min/mg (Fig. 5.2c) under the cobalt condition, 




Figure 5.2 Kinetic study of MDDEF with two substrates under the condition with 
Co
2+
. (a) Enzymatic reactions were performed at varying concentrations of MgATP (50, 
100, 200, 400, 600, 800 and 1000 M) and a saturating concentration of MVAPP (300 
M). Kinetics data were fitted into the Henri & Michaelis & Menten equation (v = 
Vmax[S]/(Km + [S])). KmMgATP was 188 ± 13 M and Vmax is 9.5 ± 0.3 mol/min/mg (b) 
Enzymatic reactions were performed at varying concentrations of MVAPP (10, 15, 25, 
50, 100, 200 and 300 M) and a saturating concentration of MgATP (1000 M) and the 
KmMVAPP value was 39.3 ± 4.0 M. (c) The values of capacities of enzyme-couple 
reactions with the addition of either cobalt (10 mM) or magnesium (10 mM) were 
determined at fixed concentrations of ADP (400 M), phosphoenolpyruvate (400 M) 
and NADH (400 M). The assay under the cobalt condition can measure the rate of an 
enzymatic reaction up to 85.4 ± 2.8 mol/min/mg, and the assay under the magnesium 











 Since we knew cobalt can be an alternative ligand for the reaction, we assumed 
that cobalt could bind to the metal binding site(s) to perform its function. To test if there 
are metal-binding sites in the closed form of MDDEF in complex with ligands, we 
replaced magnesium with cobalt during the soaking process. We have obtained data sets 





) from synchrotron and home-source radiation. All the data sets were 
processed in HKL2000 and structure refinement done in phenix.refine
76
. From the 
synchrotron data, we obtained a 1.95Å-resolution structure and a SA-ligand-omit map as 
depicted in Figure 5.3a. From the electron density map, we could observe two extra 
spheres of electron density in the active site. At the home source, we collected a 360° data 
set (1° oscillation per frame) and used the structure model derived from the synchrotron 
data to generate the anomalous difference map (Fig. 5.3b) calculated from the F+/F- 
separated data set. In the anomalous difference map, we could detect two strong 
anomalous signals which are from cobalt, suggesting there are two metal binding sites, 













. (a) The refined structure was calculated from the 1.95Å synchrotron data set. 




) is depicted in mesh 
and ligands in stick and sphere and water in red sphere. (b) The phases from the refined 
structure were used with the 2.34Å home-source data set. The anomalous difference map 
(5) was depicted in mesh and ligands in stick and sphere. 
5.4.3 Structural comparison provides insight into a detailed substrate binding 
mechanism of MDDEF 
 The superimposition of these four structures revealed the dynamics of the 
phosphate binding loop and the 10-4 loop upon substrate/ligand binding (Fig. 5.4). In 
the closed conformation of MDDEF, two loops were found to bend to the active site to 
interact with ligands. In MDDEF-MVAPP-AMPPCP-Mg
2+
, two loops were far from the 
active site and their conformations were found to be different from those in MDDEF-
MVAPP-ADPBeF3-Mg
2+
 (9.5 Å difference in the 10-4 loops and 11.1 Å difference in 
the phosphate binding loops in the open and closed forms of MDDEF) (Fig. 5.4).  
 We obtained open and closed structures of MDDEF with ligands, and the next step 
would be to confirm these represent the initial binding or intermediate conformation right 
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before enzyme catalysis. In the literature, the MDD family of proteins belongs to the 
GHMP kinase family (galactokinases, homoserine kinases, mevalonate kinases and 
phosphomevalonate kinases) sharing a common 3D structure fold. MDD has been 
identified to trigger ATP-dependent decarboxylation of MVAPP in a mechanism where 
the -phosphoryl group of ATP has been suggested to transfer to the 3’-OH group of 
MVAPP before decarboxylation, meaning the -phosphoryl group of ATP would have to 
be close to the 3’-OH group of MVAPP before catalysis.  
 By measuring the distances in these two complexes, we determined the distance 
between the 3’ oxygen atom of MVAPP and the -phosphorous atom of AMPPCP to be 
6.1 Å (Fig. 5.1d), and the distance between the 3’ oxygen atom of MVAPP and the 
beryllium of ADPBeF3 to be 3.5 Å (Fig. 5.1f), respectively. The distance measurement 
described above allows us to confirm that the closed form of MDDEF (the model from our 
crystal structure of MDDEF-MVAPP-ADPBeF3-Mg
2+
) would be a conformation right 
before MDDEF enzyme catalysis and the open conformation of MDDEF (the model from 
our crystal structure of MDDEF-MVAPP-AMPPCP-Mg
2+
) would be an intermediate state 
in which the second substrate loosely attaches onto the MDDEF protein, implied by a 
large Ki value of AMPPCP in the previous kinetic study of MDD from chicken
72
 and our 
preliminary enzymatic study (data not shown).  







, represent an apo 
form, a first-substrate bound structure, a two-substrate bound structure in an opened 
conformation and a two-substrate transition state intermediate in a closed conformation, 
respectively. We analyzed the interactions between MDDEF and its ligands, shown as 
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protein-ligand interaction profiles summarized in Table 5.2 From these interaction 
profiles, we were intrigued to observe changes in the interaction patterns from those 
structures. Most of the residues were found to be relatively stationary, forming stable 
contacts with ligands; however, we identified some residues that interact with ligands 
differently in the three bound forms of MDDEF (Gln68, Lys71, Ser106, Lys 187 and 



















Figure 5.4 Overlay of unbound and bound forms of MDDEF structures (a) The 
cartoon models of MDDEF–SO4
2-
 (white), MDDEF-MVAPP (yellow), MDDEF-MVAPP-
AMPPCP-Mg
2+
 (magenta) and MDDEF-MVAPP-ADPBeF3-Mg
2+
 (blue) are depicted and 
covered with a transparent surface from MDDEF–SO4
2-
 (white). The greatest distance 





 is 9.5 Å as indicated by a red arrow (measured between the C carbons 





 is determined to 
be 11.1 Å and as indicated by a black arrow (measured between the C carbons of A101 


















Table 5.2The interaction profile 
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 The maximum distance cutoff between the hydrogen donor and the acceptor was set at 3.5 Å 
 
 Gln68 and Lys71 residues are located in Helix 1, Ser106 in Helix 2, and 
Ser191 in Helix 4, and the gain or loss of interaction between these residues and 
MDDEF implies that Helix 1, Helix 2 and Helix 4 might also change their positons in 
different states of substrate binding and enzyme catalysis. By superimposing the crystal 
structures described above, we could further track the differences in the helical center 
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among these helices in these four structures. For Helix 1, the center of this helix moves 
into four distinct positions in the four structures (1:apo MDDEF (MDDEF-SO4
2-
); 2: first-
substrate-bound MDDEF  (MDDEF-MVAPP); 3: two-substrate-bound open conformation 
of MDDEF (MDDEF-MVAPP-AMPPCP-Mg
2+
); 4: two-substrate-bound closed 
conformation of MDDEF (MDDEF-MVAPP-ADPBeF3-Mg
2+
), Fig. 5.5a). From the 
different positions of 1 in these four structures, we could imagine the helix movement 
during the substrate binding event, and the movement was associated with the changes of 
the interaction profiles between these two residues and ligands in these structures (Fig. 
5.5b). 
 Ser106 in Helix 2 has also been identified to be involved in ligand binding in 
this study; we observe that the center of 2 shifted in these four structures (Fig. 5.5c and 
d). Helix 2 appears to move on the binding of MVAPP. From our structural observation 
in MDDEF-MVAPP, the center of 2 (Fig. 5.5c, Position 2) moved to a position closer the 
active site, if compared with the 2 position in the apo MDDEF (Fig. 5.5c, Position 1). 
However, no direct contact has been found between this -helix and MVAPP within 
possible hydrogen bonding distance (Hydrogen bond donor to acceptor < 3.5 Å). 
Nonetheless, the binding of MVAPP could cause conformational changes in the active 
site and prepare the active site environment for the subsequent steps of ligand binding 





, we did observe that the S106 residue composes a part of the metal 
binding site (Fig. 5.5d). In MDDEF-MVAPP-AMPPCP-Mg
2+
, the distance between Mg
2+
 
and -oxygen of S106 was determined to be 2.7 Å; in MDDEF-MVAPP-ADPBeF3-Mg
2+
, 
the distance between Mg
2+
 and -oxygen of S106 was measured to be 1.95 Å (Table 5.2). 
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Again, the distance difference of Mg
2+
-O in these two structures is also correlated and 
consistent with the differences of 2 centers in these two structures (Fig. 5.5c, Position 3 
and 4).  
 Ser191 is another conserved residue among the MDD family of proteins 
suggested as a key residue for catalysis and MVAPP binding
67
. A S-to-A mutation at this 
site has found to change the interactions between MVAPP and the key residues in the 
active site (D283 and R144 in MDD from S. epidermidis)
67
. Ser191 is located at the N-
terminus of Helix 4, and forms a hydrogen bond with the pyrophosphoryl group of 
MVAPP in MDDEF-MVAPP (Fig. 5.5f, Table 5.2). Thus, Ser191 is suggested to be 
involved in MVAPP binding, and correspondingly, the 4 helix center moves closer 
towards the active site (Fig. 5.5e, Position 2) than that in the apo MDDEF (Fig. 5.5e, 
Position 1). The centers of 4 in MDDEF-MVAPP-AMPPCP-Mg
2+
 (Fig. 5.5e, Position 3) 
and MDDEF-MVAPP-ADPBeF3-Mg
2+
 (Fig. 5.5e, Position 4) do not differ from the one in 
MDDEF-MVAPP. However, Ser191 in MDDEF-MVAPP-ADPBeF3-Mg
2+
 changes its 
sidechain orientation, and new hydrogen bonding forms between Ser191 and Lys187, a 
conserved residue from the 10-4 loop (Fig. 5.5f). Interestingly, Ser191 was found to be 
involved in the interactions with MVAPP and the -phosphoryl group of AMPPCP in 
MDDEF-MVAPP-AMPPCP-Mg
2+
, but the interactions no longer exist when all the 
ligands are at their catalytically favored positions and the two loop close the entrance of 
















Figure 5.5 Movements of Helix 1, 2 and 4 and dynamic residues in the unbound 
and bound forms of MDDEF. Four structures, MDDEF-SO4
2-
 (white), MDDEF-MVAPP 
(yellow), MDDEF-MVAPP-AMPPCP-Mg
2+
 (magenta) and MDDEF-MVAPP-ADPBeF3-
Mg
2+
 (blue), are superimposed for the comparison of helices and residues. Ligands 
(MVAPP, ADP, BeF3
-
 and 2 Mg
2+
 ions) from MDDEF-MVAPP-ADPBeF3-Mg
2+
 are 
represented in stick and sphere in (a), (b), (c), (d), (e) and (f). The centers of helices 
(Helix 1, 2 and 4) are represented by red sticks assigned with serial numbers (1: 
MDDEF-SO4
2-





). (a) The centers of 1 in these four structures are labeled with 
numbers, respectively. (b) The interacting residues, Q68 and K71, in these four structures 
are drawn in stick and colored corresponding to the cartoon models. (c) The centers of 2 
are correspondingly labeled as described above. (d) The interacting residue, S106, in 
these four structures is drawn in stick and colored correspondingly. (e) The centers of 4 
are labeled in the same manner. (f) The interacting residue, S191, in these four structures 
is drawn in stick and colored corresponding to the cartoon models. K187 in MDDEF-
MVAPP-ADPBeF3-Mg
2+
















 In the ATP-dependent decarboxylation reaction of MDD, divalent metal ions have 
been suggested to be crucial for catalysis. Although under physiological conditions, Mg
2+
 
is thought to be the essential ligand, other divalent ions were also examined to see if they 






. In X-ray crystallography, metal ions can be 
identified based on either anomalous signals produced at specific absorption wavelength, 
the metal ion coordination patterns in the complexes, or the electron density. However, 
magnesium is known to not produce detectable anomalous signals in most of cases, and 
its electron density is not that different than a water molecule, so usually magnesium is 
located based on the octahedral six-coordinate pattern formed by liganding atoms. In the 
closed conformation of MDDEF (MDDEF-MVAPP-ADPBeF3-Mg
2+
), the electron 
densities of MVAPP and ADPBeF3 were identified; however, two remaining spherical 
densities suggested that they belong to two magnesium ions. We then did a soaking 
experiment under the condition with 10 mM cobalt ions and collect X-ray diffractions on 





 indicated two cobalt ions in the active site and thus 
suggested that two spherical densities in MDDEF-MVAPP-ADPBeF3-Mg
2+
 belongs to 
magnesium ions. We further compared these two structures by superimposition. The 







 were nearly identical (r.m.s.d. = 0.17 Å) (Fig. 5.6a). The actives-site ligands were 
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also well-superimposed; however, there is a significant difference between these two 
structures in the metal binding site (Fig. 5.6b). This is most likely due to the different 




), although the specific metal might contribute. 
 
 












 (orange) and MDDEF-MVAPP-ADPBeF3-Mg
2+
 (blue) 
were shown in stereo. (b) The superimposition of ligands of two structures is shown in 
stereo with residues and molecules labeled. 
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5.5.2 A conserved Ser106 residue in Helix 2 functions as an anchoring point for 
metal binding 
 A conserved serine residue (Ser107 in MDDSE) was previously defined as an 
anchoring point for the binding of -phosphoryl group of ATP in the case of MDD from 
Staphylococcus epidermidis
59,67
 with a functional study that indicated the mutation on 
this residue dramatically affects the enzymatic activity (Fig. 5.7a). In our study, this 
conserved serine residue (Ser106) has been clearly identified to be involved in binding 
the metal ion (Mg
2+
 in our case) (Fig. 5.7b) In addition, the -thiophosphate of ATPS 
was sitting in the same site as one of the two metals (MG1) in our structure (MDDEF-
MVAPP-ADPBeF3-Mg
2+
)(Fig. 5.7c). In the MDDSE 2fo-fc (Fig. 5.8a) and fo-fc (Fig. 
5.8b) maps of the tertiary structure of MDDSE (4DPT), there is some indication of a 
problem in their interpretation of the ligand architecture and the role of the conserved 
serine residue due to the negative peaks around the -thiophosphate of ATPS (Fig. 5.8b). 
In their model, the distance between the -phosphorus of ATPS and the 3’-oxygen of 
FMVAPP was measured to be 5.5Å (Fig. 5.8a and c), which is too long for a phosphoryl 
transfer reaction to occur. In our crystal structure of MDDEF-MVAPP-ADPBeF3-Mg
2+
, 
the distance between the beryllium of ADPBeF3 and the 3’-oxygen of MVAPP was 
measured to be 3.5Å (Fig. 5.8b and c). These observations suggest that our structural 




Figure 5.7 The structural models of MDD from Staphylococcus epidermidis (MDDSE-
FMVAPP-ATPS, PDB: 4DPT) and Enterococcus faecalis (MDDEF-MVAPP-
ADPBeF3-Mg
2+
). (a) The ligands, FMVAPP and ATPS, in the active site of MDDSE-
FMVAPP-ATPS. The distance between the 3’-oxygen of MVAPP and the -phosphorus 
of ATPS is 5.5 Å. Ser107 is indicated. (b) The ligands, MVAPP, ADPBeF3 and 2 
magnesium ions (MG1 and MG2), in the active site of MDDEF-MVAPP-ADPBeF3-Mg
2+
. 
The distance between the 3’-oxygen of MVAPP and the -phosphorus of ATPS is 3.5 Å. 
(c) The stereo of the superimposition of the structural model from (a) and (b). The 
conserved Asp residues in both structures (D283 in MDDSE-FMVAPP-ATPS and D282 
in MDDEF-MVAPP-ADPBeF3-Mg
2+





Figure 5.8 The 2Fo-Fc and Fo-Fc maps from the complex structure of MDD from 
Staphylococcus epidermidis (MDDSE-FMVAPP-ATPS, PDB: 4DPT). (a)  The 
extracted 2fo-fc (1) electron density maps around active-site ligands are depicted in blue 
mesh. (b) The extracted fo-fc (3) electron density maps around active-site ligands are 
depicted in green mesh (positive peaks) and red mesh (negative peaks). (a) and (b) are 










5.5.3 New insight into a detailed enzyme mechanism of MDDEF 
 To imagine the physical steps of the MDDEF enzymatic reaction, here we propose 
a substrate binding model (Fig. 5.9) with conformational changes. The binding of 
MVAPP causes initial structural rearrangements, including the positioning of the 10-4 
loop and three helices (1, 2 and 4) shifting positions. We believe that the movement 
of 1 toward the active site create suitable binding site for ATP and make ATP binding 
stronger. The binding of ATP would then stabilize the phosphate binding loop and also 
bring one magnesium ion to the active site to neutralizing the negatively charged 
environment produced by the pyro- and tri-phosphoryl moieties of both substrates. 
Interestingly, AMPPCP in MDDEF-MVAPP-AMPPCP- Mg
2+
 binds the MDDEF-MVAPP 
complex differently from ADPBeF3 in MDDEF-MVAPP-ADPBeF3-Mg
2+
 in the adenosine 
(Fig. 5.10a) and the triphosphate-mimicking moieties (Fig. 5.10b), which are 
corresponding to the interaction between ligands and the MDDEF enzyme (Table 5.2). 
This outcome suggests that the --bridging oxygen of ATP would be a checkpoint during 
in the substrate binding event because it serves as an anchoring point for the phosphate 
binding loop to move toward the active site and form interactions with ATP. The second 
magnesium ion appears to fit into the active site before the close of the active site 
entrance for catalysis. Although the angles between helical centers in different structures 
may vary due to the different alignment methods, we determined the interaction patterns 
between active site ligands and the protein to confirm that the angular changes were 






Figure 5.9 A proposed substrate binding model of MDDEF during enzymatic 
reaction. Four structures (1-4) represent the four states during the enzymatic reaction 1: 
an unbound form of the MDDEF protein. In this state, the phosphate binding loop and the 
10-4 loop are dynamic. 2: a structure of MDDEF bound with its first substrate, MVAPP. 
The binding of MVAPP triggers conformational changes and the 10-4 loop (yellow) 
becomes ordered. 3: an open conformation of MDDEF in complex with MVAPP and ATP. 
The binding of ATP stabilizes the phosphate binding loop (magenta, top). 4: a closed 
conformation of MDDEF in complex with MVAPP and ATP after conformational 
rearrangement from the opened conformation. In this state, the two loops swing and close 










Figure 5.10 Structure comparison of ligands in the active site of the crystal 
structures of MDDEF-MVAPP-AMPPCP-Mg
2+
 and MDDEF-MVAPP-ADPBeF3- 
Mg
2+
. Ligands and residues involved in the binding of ATP from MDDEF-MVAPP-
AMPPCP-Mg
2+
 are colored in black. Ligands and residues from MDDEF-MVAPP-
ADPBeF3-Mg
2+
 are colored in blue. (a) The difference between the adenosine moieties of 
AMPPCP and ADPBeF3 in these two structures. (b) The difference between the -
phosphate of AMPPCP and BeF3
-








Table 5.3 Comparison of helix angles in the unbound and bound forms of MDDEF 
Crystal structure   
Angle between helices in A 
and B (°) 
A B   1 2 4 
MDDEF-SO4
2-
 MDDEF-MVAPP  4.9  4.0  11.0  
MDDEF-MVAPP MDDEF-MVAPP-AMPPCP-Mg
2+












4.9  7.2  11.1  
* The angles were obtained using the Pymol script “AngleBetweenHelices” created by Thomas 
Holder. 
 The conserved aspartate residue (D282 in MDDEF) has been recognized as a 
catalytic residue for deprotonization of the 3’-OH group of MVAPP. It is believed that 
the intermediate 3’-O
-
-MVAPP would attack the -phosphoryl group of ATP to initiate the 
phosphoryl transfer reaction, followed by the spontaneous dephosphorylation and 
decarboxylation of the intermediate ligand 3’-phosphate-MVAPP. In the closed form of 
MDDEF (MDDEF-MVAPP-ADPBeF3-Mg
2+
), we observed that the distance between the 
phosphoryl donor (O of ADP) and the acceptor (3’-O of MVAPP) was measured to be 
5.8 Å. In the literature, the Pauline bond order calculation has been frequently used for 
determining either an associative or dissociative phosphoryl transfer mechanism in 
protein kinases or phosphatases
96
. The Pauline bond order is calculated using Equation 
5.1, where D(n) is the half distance between the phosphoryl donor and acceptor, D(1) is the 
single bond distance (1.73 Å for the P-O bond) and n is the bonding order. 
 






 By using this equation with the experimental 5.8 P-O distance (Fig. 5.11), n was 
calculated to be 0.011, meaning that the phosphoryl transfer 1.1 % associative and 98.9% 
dissociative. Coordinate uncertainty exists in a refined structure model, and there are 
ways to estimate the coordinate uncertainty
97
. We used coordinate error for the estimation 
since it also takes the diffraction-component precision index (DPI) and B-factor of each 
atom into consideration
98
. If the coordinate error (0.28Å) in this structure is considered, 
the bond order in the transition state of phosphoryl transfer would range from 0.280 
(72.0% dissociative) to 0 (100.0% dissociative). This result suggested that if both the 
phosphoryl donor and acceptor do not change their positons during the phosphoryl 
transfer reaction, the reaction would likely be dissociative phosphoryl transfer. In the 
closed structure, the ligands are found to be tightly packed in the active site; any 
movement of MVAPP and/or ADP would cause severe steric clashes. Assuming no 
substantial movement of the MVAPP molecule, we suggest that there would be a 
dissociative phosphoryl transfer reaction taking place during the chemical steps of 





Figure 5.11 The distance measurement between the in-line phosphoryl transfer 
donor and acceptor. The distance between 3’-O of MVAPP (acceptor) and O of ADP 
(donor) was measured to be 5.8 Å.  
 In the closed conformation, a dissociative phosphoryl transfer would occur and 
produce a metaphosphate ion in the transition state of catalysis. The metaphosphate ion 
would be escorted possibly by the metal ions and the Lys187 residue to the 3’-OH group 
of MVAPP to form 3’-phosphate-MVAPP, followed by spontaneous dephosphorylation 















Figure 5.12 A proposed dissociative phosphoryl transfer mechanism of MDDEF 
during the enzymatic reaction. 1: de-protonization of the 3’-OH group of MVAPP (red) 
is done by D282.  2: dissociative phosphoryl transfer occurs and the metaphosphate 
(blue) would be produced. 3: The metaphosphate would attach to the 3’-O
-
 group (red) of 
MVAPP. And 4: dephosphorylation and decarboxylation would occur to form products, 
IPP, ADP, PO4
2-
 and CO2. K187 from the 10-4 loop and metal ions are involved in 
neutralizing the negatively charged environment in the active site during catalysis. The 











 The pKa value of the carboxyl group of Asp in solution is about 3.9, and the 
soaking buffer contains 50 mM sodium acetate, pH 4.6. Using Equation 5.2, where [HA] 
is the concentration of the protonated aspartate and [A-] is the concentration of 
deprotonated aspartate, we could roughly estimate that the side chain of Asp282 is 20% 
protonated. 
 











 had been 
determined under different pH conditions. In both cases, MDD enzymes showed a 50% 
enzymatic activity at pH 4.6 compared relative to the enzymatic activity determined at 
pH 7. At pH 4.6, ATP is mainly protonated to “HATP
3-“84





 is about 1.58 mM
85
. These might explain the pH effects on the 
decrease of the MDD enzymatic activity. However, the active MDD enzymes under 
acidic conditions (above pH 3) suggest the functional catalytic residues in the active site 
and the accessible binding of true substrates. In our crystal structures, the Asp282 residue 
could be partially protonated, but the majority of Asp282 in the crystal should be 
functional for the deprotonation of the 3’-OH group of MVAPP. Although we assume that 
the dissociative phosphoryl transfer might occur during the chemical steps of the 
decarboxylation, we still need experimental approaches to elucidate the detailed 




CHAPTER 6. THE DIMISHED ENZYME ACTIVITYOF THE K187A MUTANT 
REVEALS THE IMPORTANCE OF THE CONSERVED LYSINE IN THE 
ENZYME MECHANISM 
6.1 Chapter Summary 
 In the closed conformation of MDDEF (MDDEF-MVAPP-ADPBeF3-Mg
2+
), we 
observed that a conserved lysine (Lys187) forms hydrogen bonds with Ser191 and O of 
ADPBeF3 in the active site. We then created a K187A mutant of MDDEF by site-direct 
mutagenesis and determined the enzymatic activity of the K187A mutant. Intriguingly, 
the K187A mutant showed a 300-fold decrease in the enzymatic activity if compared with 
wild type MDDEF. This suggested that K187 is essential for the enzymatic reaction. To 
test if this lysine is involved mainly in substrate binding, we performed ITC experiments 
and the thermodynamic data showed that the mutation of lysine to alanine only affects the 
binding affinity between ATPS and MDDEF-MVAPP about 2 fold, suggesting that this 
residue would be mainly involved in catalysis. Our findings also implicated that the 
conserved serine residue (S191 in MDDEF) may serve as an anchoring point for 
positioning Lys187 during catalysis. 
6.2 Introduction 
 Positively charged residues, such as lysine or arginine, have been shown to play 
important roles in substrate binding or neutralizing the negatively charged active site in 
kinases
96,101
. MDD is a member of GHMP kinase family of proteins (galactokinase, 
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homoserine kinase, mevalonate kinase, phosphomevalonate kinase)
59
 and it triggers ATP-
dependent decarboxylation of MVAPP. In MDDEF, the conserved K71 (Arginine in 
eukaryotes) and Arg144 are known to be responsible for the binding of MVAPP. From 
our crystal structures, another conserved lysine residue (Lys187) has also been found to 
be located in the active site when the protein binds its two substrates and ligands. This 
implies that Lys187 may also play a pivotal role “transiently” during catalysis. Previously, 
this conserved lysine was identified to be functional in the case of MDD from rats
58
; 
however, this lysine has not yet been annotated as a key residue for catalysis or substrate 
binding
58
. In the closed conformation of MDDEF (MDDEF-MVAPP-ADPBeF3-Mg
2+
), we 
observed that Lys187 interacts with ADPBeF3 and Ser191 in the active site. This suggests 
that this residue may assist the binding of ATP and/or facilitate enzyme catalysis. To test 
that, we created the K187A mutant, determined its relative enzymatic activity versus the 
wild type MDDEF and also measured the dissociation constants between the K187A 
mutant and ligands under various conditions. These results will help us to identify the 
role of Lys187 in the MDDEF enzymatic reaction. 
6.3 Materials and Methods 
6.3.1 Site-directed mutagenesis 
 The K187A mutant was created by side-direct mutagenesis. The sequence of the 
forward primer from 5’ to 3’ is “CTTAATTAATGATGGCGAAGCAGATGTTT 
CCAGCCGTGATG”, and the sequence of the reverse primer is “CATCACGGC 
TGGAAACATCTGCTTCGCCATCATTAATTAAG”. The 50 l PCR solution contains 
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the forward and reverse primers (1 M, respectively), dNTP (200 M of each), Phusion 
HF buffer (1X), template DNA (0.1 l ~ 1 l), DMSO (2%), Phusion DNA polymerase 
(one unit) and sterile water. The PCR program was set to be 1 cycle of denaturation (95℃, 
one minute), 25 cycles of the 3-step reaction (1. Denaturation, 95℃, 30 seconds; 2. 
Annealing, 62℃, 30 seconds; 3. Extension, 72℃, 5 minutes and 30 seconds), one cycle 
of the final extension (72℃, 10 minutes) and overnight incubation at 4℃. After the PCR 
procedure, the old template containing methylated DNA was then digested by Dpn1 (1 l) 
for one-hour treatment at 37℃.  
6.3.2 Sequence alignment and structural annotation 
 The sequences of MDD proteins from organisms (Enterococcus faecalis; 
Enterococcus faecium; Staphylococcus epidermidis; Staphylococcus aureus; 
Streptococcus pyogenes; Listeria monocytogenes; Homo sapiens; Trypanosoma brucei; 
Mus. musculus; Xenopus tropicalis; Bos taurus; Arabidopsis thaliana) were aligned using 
EBI Clustalw Omega
82
. The secondary structure elements were drawn using 
ESPript3.0
102
 based on the structural model of MDDEF in complex with MVAPP, ADP, 








6.3.3 Enzymatic activity of wild type MDDEF and the K187A mutant 
The enzymatic activity of MDDEF and the K187A mutant was determined using an 
ATP/NADH enzyme-coupled assay, respectively. Each reaction was performed at 30℃ 
under the buffer condition (100 mM HEPES, pH 7.0, 100 mM KCl, 10 mM MgCl2, 0.2 
mM NADH, 0.4 mM phosphoenolpyruvate, 4 units of pyruvate kinase, 4 units of lactate 
dehydrogenase, and 100 nM MDDEF
59
). Initial velocity of each reaction was determined 
at a concentration of ATP (800 M) and MVAPP (200M). Relative enzyme activity of 
the K187A mutant was calculated by dividing the average enzymatic velocity of the 
K187A mutant by the average enzymatic velocity of wild type MDDEF.  
6.3.4 Isothermal titration calorimetry (ITC) experiments 
 The preparation of the TEV-treated K187A mutant proteins was the same as the 
preparation of TEV-treated wild type MDDEF described previously. The protein solution 
was dialyzed against the same buffer used in the enzymatic reaction and the final protein 
conce
solutions (260 l) were titrated with ligands (MVAPP, ATP and ATPS) which were also 
prepared in the same buffer and the concentration of each titrant was optimized in 
different experiments. The temperature for ITC experiments was set at 25 ℃ . Each 
experimental profile composed of the addition of an initial aliquot of 0.4 l, followed by 
22 aliquots of 1.8 l of the substrate or ligand solution. The time interval between two 
consecutive injections was 180s. The experimental designs were done using the 





and analyzed using the one-site model in SEDPHAT
93
. Figures were generated using 
GUSSI. 
6.4 Results 
 To investigate the role the conserved lysine (K187 in MDDEF) in the enzymatic 
reaction, we performed site-directed mutagenesis to create the K187A mutant of MDDEF 
and the PCR result was shown in Figure 6.1. The protein expression and purification 
procedures were the same as used in our previous study of wild type MDDEF. French 
press was employed to break down the cells and the supernatant containing soluble 
proteins was collected and pumped through a Ni-NTA column. The His-tagged K187A 
mutant proteins were trapped on a Ni-NTA column and eluted by increasing 
concentrations of imidazole in buffer B described in the previous chapter, and the 
purification profile, SDS-PAGE analysis and TEV-treatment results were shown in 
Figure 6.2. We have successfully purified the K187A mutant form of MDDEF and those 
proteins were used for the determination of the relative enzymatic activity and the Kd 





Figure 6.1 The PCR product of K187A mutant. The K187A mutant was created by 
side-direct mutagenesis. The sequence of the forward primer from 5’ to 3’ is 
“CTTAATTAATGATGGCGAAGCAGATGTTTCCAGCCGTGATG”; the sequence of 
the reverse primer is “CATCACGGCTGGAAACATCTGCTTCGCCATCATTAATTAA-
G”. The DNA latter was loaded in the first line and the 3-kb was indicated. The plasmid 
of MDDEF was loaded in the second line for estimating the size of the PCR product of the 












Figure 6.2 Protein purification of K187A mutant. (a) The purification profile of the 
K187A mutant. Fractions from 8 through 17 were polled for further dialysis. (b) Cell 
pellets before induction (w/o induction), after IPTG induction (IPTG induction), pellet 
(Pellet) and supernatant (supernatant) after French press, protein solution after the Ni
2+
 
column (flow through) and protein eluted fractions (8, 10, 12, 14, 16 and 17) were 
examined by SDS-PAGE after protein purification. (c) Protein solution of the K187A 







 From our previous enzymatic study, we determined the Kdmvapp value to be about 
40 M, and the KdATP value was about 160 M. We then performed enzymatic reactions 
for both wild type MDDEF and the K187A mutant at about saturated concentrations of 
both substrates in the reaction buffer (MVAPP = 200 M, ATP = 800 M). The enzymatic 
activity of the K187A mutant was calculated and its relative enzymatic activity was 
expressed as a percentage of wild type MDDEF enzymatic activity. A value of 0.35% 
activity relative to the value of wild type MDDEF indicated that this conserved lysine 
residue (Lys187) is essential for the enzymatic reaction (Fig. 6.3). Although we did not 
determine the KmMVAPP and KmMgATP values for the K187A mutant, we performed ITC 
experiments to determine the actual Kd values of MVAPP and ATPS to infer that if the 
lysine affects substrate binding. 
 
 
Figure 6.3 Relative enzyme activity of the K187A mutant compared to MDDEF. The 
enzyme activities of MDDEF and K187A mutant of MDDEF had been determined at 
saturating concentrations of two substrates (MVAPP = 200 M; MgATP = 800 M) and 
normalized by the means of wild-type MDD enzyme activity. The means and the standard 































 All the ITC experiments for the K187A mutant were performed (Fig. 6.4a to d) 
and the experimental parameters were basically similar to what we used for determining 
Kd values in the cases of wild type MDDEF. All the derived thermodynamic parameters 
are listed in Table 6.1. First, the KdMVAPP value was determined as 8.7 ± 5.4 M (Table 
6.1a), which is about a two-fold decrease compared with the value of KdMVAPP in wild 
type MDDEF (20.4 ± 9.3 M, Table 4.1a). A two-fold difference in binding affinity (1/Kd) 
may not be considered significant in general. The KdATP value was 495 ± 91 M (Table 
6.1b), which is about 1.5-fold greater than KdATP in MDDEF (288 ± 36 M, Table 4.1b). 
And the KdATPS value was 182 ± 36 M (Table 6.1c), which is about equal to the value of 
KdATPS in MDDEF (215 ± 8 M, Table 4.1c). In the presence of excessive MVAPP in the 
K197A protein solution (100 M of K187A + 1 mM of MVAPP), KdATPS was determined 
as 58.2 ± 13.2 M (Table 6.1d), and under the same condition in the case of wild type 
MDDEF, the difference in Kd is about two-fold (25.4 ± 5.5 M, Table 4.1d). However, the 
KdATPS is 4-fold smaller than KdATPS of 182 M determined under the condition without 
MVAPP (Table 6.1c). These results suggest that the prerequisite binding of MVAPP to the 
K187A mutant can also enhance the binding of ATPS. Although the K-to-A mutation 
does not cause significant changes in substrate binding ability, this mutation dramatically 
affect the enzymatic activity by 300 folds (Fig. 6.3), which indicates that this Lys187 may 









Figure 6.4 The original titration curve of ITC experiments. (a) The K187A mutant 
(100 M) was titrated with MVAPP (1 or 2 mM). (b) The K187A mutant (100 M) was 
titrated with ATP (3 mM). (c) The K187A mutant (100 M) was titrated with ATPS (3 
mM). (d) The K187A mutant (100 M) was pre-incubated with MVAPP (1 mM) and then 
titrated with ATPS (2 mM). The thermodynamic parameters of each experiment are 
listed in Table 6.1. 
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Table 6.1 Thermodynamic parameters* 











a K187A  
(100 M) 
MVAPP                   
(1 mM 
or 2 mM) 
8.7 ± 5.4 -7.1 ± 0.3 -0.6 ± 0.1 6.5 ± 0.2 21.9 ± 0.7 




495 ± 91 -4.5 ± 0.1 -4.4 ± 1.5 0.1 ± 0.9 0.4 ± 2.9 




182 ± 36 -5.1 ± 0.1 -6.3 ±0.4 -1.2 ± 0.2 -4.0 ± 0.8 
d K187A  





58.2 ± 13.2 -5.8 ± 0.1 -2.1 ± 0.4 3.7 ± 0.2 12.4 ± 0.8 
*Titration experiments were done at 25℃.  





) and the standard deviation 
of ΔG () is calculated from the equation: σ =  √ln (1 +  
𝑣
𝑚2
), where m is the mean of the association 
constant (Ka) and v is the variance of Ka derived from each ITC experiment. 
# The mean of TS () is derived from the difference between the means of G (1) and H ( 2) 
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 The results of multiple sequence alignment and crystal structures show that there 
are several lysine and arginine residues in the active site, and many of them have been 
annotated for the binding of substrates (Fig. 6.5). From our enzymatic and 
thermodynamic studies, the conserved Lys187 in the un-conserved 10-4 loop is 
suggested to be involved mainly in the chemical steps of catalysis. In our crystal 
structures, we knew that this 10-4 loop swings to close the substrate entrance when all 
the ligands are bound in the active site. This suggests that this conserved Lys187 could be 
transiently involved in the reaction during catalysis. Interestingly, the Ser191 residue also 
rotated its sidechain to interact with Lys187 in the closed conformation of MDDEF (Fig. 
5.5f), which implies that this conserved serine may also play roles during the enzymatic 
reaction. This serine has been reported to be important for the enzymatic activity, yet its 
role has not been annotated.  From our structural observations, this serine may also serve 







Figure 6.5 Extracted multiple sequence alignment. Sequences corresponding to the 
organisms (E. faecalis; E. faecium; S.epidermidis; S. aureus; S. pyogenes; L. 
monocytogenes; H. sapiens; T. brucei; M. musculus; X. tropicalis; B. taurus; A. thaliana) 
were aligned using Clustal Omega 
82
 and the extracted figure containing structural 
elements and the sequence alignment was generated using ESPript3.0 
102
. Identical 
residues and homologous residues are boxed and shaded in black and white based on 
BLOSUM matrix (BLOSUM62). Residues characterized to be functionally important 
from the literature among MDD proteins are marked with solid triangles
58,59,67
; residues 
involved in substrate interaction are marked with empty stars; the phosphate binding loop 








CHAPTER 7. HIGH-THROUGHPUT SCREENING FOR MDDEF SPECIFIC 
DRUG DISCOVERY 
7.1 Chapter Summary 
 The human mevalonate diphosphate decarboxylase is a member of the MDD 
family of proteins and performs the same decarboxylation reaction of MVAPP as MDDEF 
to produce isopentenyl diphosphate. The active site environment of MDD proteins is 
highly conserved, and that makes specific drug development against MDDEF challenging. 
In addition to performing high-throughput screening (HTS) for selecting MDDEF potent 
inhibitors, we will need human MDD as a negative control for achieving compound 
selectivity against MDDEF. We performed auto-induction to successfully produced 
functional human MDD and purified proteins to homogeneity using Ni2+-NTA affinity 
chromatography. Meanwhile, we established a high-throughput screening assay method 
for identifying potential inhibitors against MDDEF. Although we had 14 compounds 
identified from HTS, the follow-up examination indicated that the leads from HTS are 
false positive ones. We will focus on improving HTS assay methods for the future 
MDDEF drug discovery. 
7.2 Introduction 
 The MDD family of proteins acts on MVAPP and produce IPP, and the active site 
environment is highly conserved, which has been observed by multiple sequence 
alignment (Fig. 6.5). This indicates that even the primary sequences of human MDD and 
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MDDEF share < 30% sequence identity, the overall structure of MDD proteins and their 
key residues in the active site for substrate binding and catalysis are well conserved
69
. In 
order to identify selective inhibitors against MDDEF instead of human MDD, we will 
need human MDD and perform assays to exclude compounds which have inhibitory 
ability against human MDD proteins. In the literature, human MDD has been successfully 
produced and tested enzymatically
69
; however, in our preliminary results, we would not 
be able to produce functional proteins using the same reported protocol, so we will need 
to modify the human-MDD purification strategy. In addition, the coupled enzyme 
reaction (pyruvate kinase/lactate dehydrogenase) method has been used in high-
throughput screening (HTS) for identifying potential inhibitors against the mevalonate 
diphosphate decarboxylase from Streptococcus pneumonia (MDDSP). Previously we have 
established an in vitro assay method for studying MDDEF enzyme kinetics. This can then 
be modified for HTS against MDDEF. 
7.3 Materials and Methods 
7.3.1 Cloning, expression and purification of the recombinant form of Human 
MDD 
 The plasmid (pET-23d) encoding the hMDD gene fragment was purchased from 
Addgene
69
 (pET-23d-hMDD). The sequence was confirmed by the low-throughput 
sequencing center at Purdue. E. coli BL21 (DE3) cells were transformed with pET-23d-
hMDD. The transformed cells were cultured in the auto-induction medium (6 g/L 
Na2HPO4, 3 g/L KH2PO4, 20 g/L tryptone, 5 g/L yeast extract and 5 g/L NaCl, pH 7.2) 
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supplemented with Ampicillin (100 mg/ml) at 37 ℃ to an A600nm of 0.3. Auto-induction 
solution (10 ml of 60% glycerol; 5 ml of 10% glucose; 25 ml of 8% lactose) was added to 
the bacterial culture to induce protein expression at 25 ℃  for 20 hours. Cells were 
harvested by centrifugation at 8000 rpm for 10 minutes, re-suspended in binding buffer 
(50 mM of sodium phosphate at pH 7.4, 300 mM of NaCl, and 10 mM of imidazole), and 
lysed to homogeneity by French Press at 1500 psi. After centrifugation at 15000 rpm for 
15 minutes, His-tagged hMDD proteins were soluble in supernatant and then trapped on a 
Ni
2+
-NTA column. The proteins were eluted from the column with the increasing 
gradient of elution buffer (50 mM sodium phosphate, pH 7.4, 300 mM NaCl, and 300 
mM imidazole) from 0% to 100%. Eluted fractions of hMDD were collected and desalted 
in dialysis buffer (25 mM Tris-HCl, pH 8, 100 mM NaCl, and 10 mM MgSO4). The 
protein solution was concentrated to 1.6 mg/ml by ultrafiltration and stored at -20 ℃. 
7.3.2 Comparison of enzymatic activity of human MDD and wild type MDDEF 
 Enzymatic activity of MDDEF and human MDD was determined using an 
ATP/NADH enzyme-coupled assay, respectively. Each reaction was performed at 30℃ 
under the buffer condition (100 mM HEPES, pH 7.0, 100 mM KCl, 10 mM MgCl2, 0.2 
mM NADH, 0.4 mM phosphoenolpyruvate, 4 units of pyruvate kinase, 4 units of lactate 
dehydrogenase, and 100 nM MDDEF)
59
. Initial velocity of each reaction was determined 
at a concentration of ATP (1000 M) and MVAPP (300 M). Relative enzymatic activity 
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of human MDD was calculated by dividing the enzymatic velocity of human MDD by the 
enzymatic velocity of wild type MDDEF. 
7.3.3 High-throughput screening for hit selection against MDDEF 
 An ATP/NADH enzyme-coupled assay was used for determining enzymatic 
activity of MDDEF in high-throughput screening using the LOPAC library (Sigma). Two 
kinds of master solutions were prepared separately. Master Solution A (MSA) contains 
100 mM HEPES, pH 7.0, 100 mM KCl, 10 mM MgCl2, 4 units of pyruvate kinase, 4 
units of lactate dehydrogenase, 100 M MVAPP, and 20 nM MDDEF. Master Solution B 
(MSB) contains 100 mM HEPES, pH 7.0, 100 mM KCl, 10 mM MgCl2, 2 mM NADH, 2 
mM phosphoenolpyruvate (PEP), 1 mM ATP. The assay was performed in a 1536-well 
plate format. 4 l of MSA was dispensed into each well, followed by the addition of 0.02 
l of each compound from the LOPAC library using the HTS facility in Bindley at 
Purdue. 1 l of MSB was then dispensed into each well, and MDDEF enzymatic activity 
of each well was determined by monitoring A340nm decrease. The Z-score value was 
calculated to evaluate the assay quality and each reaction was monitored at room 
temperature for 30 minutes with 30-second intervals. 
7.3.4 Follow-up assays for hit selection against MDDEF 
 IC50 values of potential hits from HTS were further determined. To determine 
IC50 values, a 1/2 serial dilution for each compound (0, 1.25, 2.5, 5, 10, 20, 40 and 80 M) 
was made with MSA and prepared in a 384-well plate. The above solution was then 
transferred to a 1536-well plate and the following procedures were the same as HTS 
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described above. Percent inhibition of MDDEF enzymatic activity was calculated and the 
IC50 value of each compound was determined by fitting the inhibition data to a 
Michaelis–Menten kinetics model using GraphPad Prism 6. 
7.4 Results 
 Humans utilize the mevalonate pathway to produce IPP. Although human MDD 
shares only 31.8 % sequence identity with MDDEF, the key residues in the active site are 
highly conserved among MDD proteins
67
. Thus, the selectivity of potent inhibitors 
against MDDEF and hMDD has to be tested. In the published paper, the human form of 
MDD can be successfully expressed in the E. coli BL21 (DE3) system using IPTG as an 
inducer
69
. Although we purchased the same plasmid-DNA and used the same expression 
protocol, we could not be able to obtain functional human MDD proteins and there was 
only a small amount of partially active proteins in the soluble part (data not shown). We 
had changed IPTG concentrations, incubation temperature, and different E. coli strains 
(RIL and AI) for protein induction; however, it was not compatible with the protein 
quality described in the original paper
69
. A large quantity of proteins was presented in the 
inclusion body, and this indicated a fast protein induction. To overcome this problem, we 
used the “auto-induction” strategy. From that, we can produce functional human MDD 
protein in E. coli BL21 (DE3) and Ni-NTA chromatography to purify human MDD to 
homogeneity. 
 We would be able to obtain the human MDD proteins eluted from the Ni-NTA 
column at an imidazole concentration of about 150 mM (Fig. 7.1a, b) and its relative 
enzyme activity compared to the wild type MDDEF was determined to be about 26.5% 
125 
 
(Fig. 7.1c). From the previously published paper, Vmax of human MDD was determined to 
be 6.1 ± 0.5 mol/min/mg, KmMVAPP was 28.9 ± 3.3 M, and KmMgATP was 690 ± 70 M
69
. 
Based on these kinetic parameters given in that paper, we could calculate enzymatic 
activity of human MDD, and it is about 25% relative to MDDEF under the condition used 
in this study. This suggests that we could produce functional human MDD proteins using 
auto-induction, and these proteins can be used as a negative control for selecting specific 




Figure 7.1 The purification profile, SDS-PAGE analysis and the relative enzymatic 
activity comparison. (a) hMDD proteins were eluted with an increasing imidazole 
concentration described above. (b) Samples from the purification steps were analyzed by 
SDS-PAGE. (c) The relative enzymatic activity of hMDD was compared with MDDEF 





 Previously we established the PK/LDH coupling system for monitoring the 
enzyme activity of MDDEF, and we have modified the experimental parameters for the 
MDDEF HTS screening. High-throughput screening was performed to identify 
compounds with potential inhibitory activity against MDDEF. The LOPAC compound 
library (1280 compounds) was tested and screening was done in Bindley Biosciences 
Center. Z factor was calculated before analyzing inhibitory activity of each compound in 
LOPAC. The Z factor of the screening test was calculated using Equation 7.1, where the 
symbol “” represents the mean of either positive or negative controls; the symbol 
“
negative represent positive controls (with MDDEF addition) and negative controls 











 A Z-score of 0.7 (greater than 0.5) in our preliminary HTS test indicated an 
acceptable assay quality. Using 1 sigma of the mean of negative controls as a selection 
criterion, 14 hits with potential inhibitory activity against MDDEF were identified after 






Table 7.1 Hits from HTS. 
1 (±)-AMT hydrochloride 
2 Gabaculine hydrochloride 
3 4-DAMP methiodide 
4 (±)-2-Amino-7-phosphonoheptanoic acid 
5 Reactive Blue 2 
6 5-Aminovaleric acid hydrochloride 
7 (±)-Nipecotic acid 
8 Mecamylamine hydrochloride 
9 Azelaic acid 
10 Benzamil hydrochloride 
11 PPNDS tetrasodium 
12 S-(-)-Carbidopa 
13 5-Fluoroindole-2-carboxylic acid 
14 GYKI 52466 hydrochloride 
 
 
After HTS, we then determined the IC50 value for each compound in the 
follow-up experiments. The follow-up experiments were conducted at varied 
concentrations of each compound from HTS. Each enzymatic reaction was monitored and 
the percent inhibition of the enzyme under different conditions was calculated using 
Equation 7.2, where “experiment” stands for measured enzymatic activity with the 
addition of varied concentrations of a given compound; “background” is readout from a 
control without enzyme and inhibitor addition; “Positive control” means measured 








 The value of percent inhibition of each data point in each compound test was 
plotted as a function of inhibitor concentrations. The inhibitory data were represented by 
the Michaelis–Menten kinetics model (GraphPad Prism 6) for obtaining the IC50 value in 
each case. Fourteen compounds were examined in the follow-up experiments, and two 
compounds, 4-DAMP methiodide and Benzamil hydrochloride were identified from the 
follow-up experiments. The compound structures and the data fitting results are shown in 
Figure 7.2. Both of them have IC50 values of 5 to 10 M. Although the follow-up 
experiments indicated these two compounds exhibited promising inhibition activity 
against MDDEF, the results cannot be reproduced when we purchased these two 
compounds and tested them manually with the in vitro assay (data no shown). In the 
discussion session, we will discuss about possible reasons for the false positive results 
from HTS and the follow-up experiments, and strategies for improving the data quality. 
 
 
Percent inhibition = (1 −
(𝑒𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡 −𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑)
(𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 −𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑)




Figure 7.2 The molecular structures and the IC50 determination of hits from the 
follow-up experiments. (a) The structure of 4-DAMP methiodine. (b) The results of 
percent inhibition of MDDEF enzymatic activity at varied concentrations 4-DAMP 
methiodine is plotted, and IC50 is indicated. (c) The structure of benzamil hydrochloride. 
(d) The results of percent inhibition of MDDEF enzymatic activity at varied 



















 In the design for the high-throughput screening and the follow-up experiments, 
we chose a 1536-well plate for loading our samples and use the dispenser to pipette 4 l 
of MSA and 1 l of MSB into each well. We found many of the experimental results 
showed “unstable” signals, meaning the absorbance readout went up and down during the 
enzymatic reaction, and those were not observed in the reactions performed in a 96- or 
384-well plate. We thought shorter light path length in a 1536-well plate and sample 
homogeneity could be issues. In the future, we might increase the volume of MSB and 
adjust the concentrations of components in both MSA and MSB. We think that the 
increase in the volume of MSB solution could reduce the effects of pipetting errors from 
the dispenser. And a larger volume of MSA-MSB mixture will also increase the path 














CHAPTER 8. STRUCTURE DETERMINATION OF ISOPENTENYL 
DIPHOSPHATE ISOMERASE 
8.1 Chapter Summary 
 In this chapter, we will be focusing on another key enzyme, the type II 
isopentenyl diphosphate isomerase from Enterococcus faecalis (IDI-2EF), in the 
isoprenoid pathway. This enzyme is downstream of the MDD enzymes and functions to 
catalyze the interconversion between IPP and DMAPP, which is another key building 
block for polyisoprenoid biosynthesis
66,103
. In our study, we aim to characterize structural 
features and differences between the unbound and FMN-bound forms of IDI-2EF for 
designing novel inhibitors which target either conformation for ceasing the enzymatic 
activity. The human isopentenyl diphosphate isomerase belongs to the type I IDI (IDI-1), 
which is different from IDI-2 family of proteins in sequence and structure
104,105
, so 
ideally we could identify compounds that can specifically bind to the active site pocket. 
We have obtained the first crystal structure of unbound IDI-2 from Enterococcus faecalis, 
and this structure will confer a structural platform for structure-based drug development 








 Isopentenyl diphosphate isomerases (IDIs) are ubiquitous enzymes in organisms
66
. 
The function of these enzymes is to interconvert IPP and DMAPP and maintain the 
balance between these two molecules in the cells
66
. It is known that IPP and DMAPP are 
compounds for biosynthesis of polyisoprenoids in living organisms, and two distinct 
pathways, the mevalonate (MVA) pathway and the methylerythritol phosphate (MEP) 
pathway (Fig. 8.1), are involved in producing IPP and DMAPP. For some organisms 
containing the MEP pathway, such as E. coli
106
, both IPP and DMAPP can be produced 
by the end of the pathway, and the isomerases function to balance the concentrations 
between IPP and DMAPP; some of organisms, such as Entorococci, Staphyllococci and 
Streptococci, contain only the mevalonate pathway
107
. Thus, the isomerases are 
considered essential for the organisms to growth because DMAPP can only be produced 






Figure 8.1 The methylerythritol phosphate (MEP) pathway and the mevalonate 
(MVA) pathway. Pyruvate and lyceraldhyde 3-phosphate are compounds for IPP and 
DMAPP synthesis in the MEP pathway. In the MVA pathway, three molecules of acetyl-
CoA are condensed to 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) followed by 4 steps 
of reactions to produce IPP. Isopentenyl diphosphate isomerases (IDI) catalyze 
IPP/DMAPP interconversion. The arrow heads represent more steps involved in both the 








 Two types of IDI proteins, IDI-1 and IDI-2, have been characterized structurally 
and functionally in the literature
103,104,108
. Although they catalyze the same reaction, they 
are distinct in structure and sequence similarity and the mechanisms differ from each 
other. In IDI-1, two conserved residues, cysteine and glutamate, are served as general 
acid/base catalysts in the active site; in IDI-2, a reduced FMN molecule is proposed to 
play a similar role for IPP/DMAPP isomerization (Fig. 8.2)
103
. Humans and enterococci 
utilize the mevalonate pathway to produce IPP and thus need IDI enzymes to produce 
DMAPP. Interestingly, the human genome encodes IDI-1, whereas the enterococci 
genome encodes IDI-2. Since IDI-1 does not share protein sequence and structure 
homology with IDI-2, IDI-2 becomes a potential therapeutic target for the treatment of 
clinical enterococcal infections. 
 
Figure 8.2 The proposed mechanisms of IPP/DMAPP isomerization by IDI-1(red) 
and IDI-2 (blue)
103
. The conserved glutamate and cysteine residues (red) in IDI-1 are 
general acid/base catalysts for IPP/DMAPP isomerization. In IDI-2, a reduced form of 




8.3 Materials and Methods 
8.3.1 Cloning, expression and purification of the recombinant form of IDI-2EF 
The IDI-2EF gene was sub-cloned into the expression plasmid pET-30a (pET-30a-
IDI-2EF). The DNA sequence was confirmed and E. coli BL21 (DE3) cell were 
transformed with pET-30a-IDI-2EF
73
. Transformed cells were cultured in LB broth 
supplemented with kanamycin (50 mg/ml) at 37 ℃ to an A600nm of 1.0. Expression of 
IDI-2EF proteins was induced by the addition of IPTG to a final concentration of 0.1 mM 
for another 4 hours at 37 ℃. Cells were harvested and protein purification steps were the 
same as described previously for MDDEF. The C-terminal His-tag can be removed from 
IDI-2EF by treatment of recombinant tobacco etch virus (TEV) protease the procedure 
was basically the same as used in the previous sessions. The protein solution was further 
dialyzed in dialysis buffer again before loaded on a Ni2+-NTA column to remove His-
tagged TEV proteases and residual His-tagged IDI-2EF. The purified IDI-2EF protein 
solution was collected from the flow through and concentrated to 5 mg/ml by 
ultrafiltration and stored at -20 ℃.  
8.3.2 IDI-2EF protein crystallization, cryo-protection and X-ray data collection and 
analysis 
 The apo-IDI-2EF crystal was obtained by mixing 3 l of 5 mg/ml IDI-2EF protein 
solution with 1l of reservoir solution (15% PEG 300, 100 mM sodium citrate, pH 5.6, 
and 100 mM MES, pH 6). The drop was equilibrated by vapor diffusion at 20 ℃ in a 
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sitting-drop plate. IDI-2EF crystals were flash-frozen in liquid nitrogen with the cryo-
protectant (30% PEG 300, 100 mM sodium citrate, pH 5.6, and 100 mM MES, pH 6). 
 The diffraction data of single apo-IDI-2EF crystal were collected both on the 
home-source X-ray radiation at Purdue and the synchrotron at Advance Photon Source 
(APS) at Argonne National Laboratory in Chicago (APS). The space group, P4212, was 





. The crystal structure of apo-IDI-2EF was solved by molecular 
replacement (phenix.phaser)
76
 using the crystal structure of IDI-2 from Bacillus subtilis 
(IDI-2BS, PDB: 1P0K) as a search model (sequence similarity: 32.6%). Structure 
refinement was done in phenix.refine
76
 and the refinement and structure statistics of apo-
IDI-2EF was summarized in Table 2. 
8.4 Results 
 Expression of IDI-2EF proteins were successfully induced by IPTG in the E. coli 
expression system (BL21). His-tag IDI-2EF proteins were trapped on a Ni
2+
-NTA column 
and then eluted with increasing gradient of imidazole (Fig. 8.3a). The sample from each 
step was analysis by SDS-PAGE (Fig. 8.3b). The tag in C-terminus of IDI-2EF was 
removed by treatment of TEV protease (Fig. 8.3c). The TEV-treated IDI-2EF protein 





Figure 8.3 The purification profile and SDS-PAGE analysis. (a) IDI-2EF proteins were 
eluted with an increasing imidazole concentration described above. (b) Samples from the 
purification steps were analyzed by SDS-PAGE. (c) The C-terminal His tag was removed 
from IDI-2EF by treatment of TEV protease under different conditions (#: dialysis buffer 
containing 25 mM HEPES, pH 8; * dialysis buffer containing 25 mM Tris-HCl, pH 8). 50 
mM of EDTA was used for stripping residual His-tagged proteins off a Ni
2+
 column.  
 
 We have obtained protein crystals of apo-IDI-2EF. The diffraction data were 
collected at the home-source radiation and the APS synchrotron, followed by the data 
process using HKL2000. The structure resolution was determined as 2.5 Å  at the home 
source and 2.1 Å  at synchrotron. The space group of the apo-IDI-2EF crystal was 
determined as P4212. The phases were solved by molecular replacement in 
phenix.phase
76
 using IDI-2 from Bacillus subtilis as a search model. Structure refinement 
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was performed using phenix.refine
76
 and detailed statistics was summarized in Table 8.1. 
The structural model of IDI-2EF was shown in cartoon in Figure 8.4. One macromolecule 
in an asymmetric unit was determined by calculating the Mathrew coefficient (Fig. 8.4a) 
and there are 8 polypeptide chains in a unit cell (Fig. 8.4b). A tetrameric feature of IDI-
2EF has known to be conserved among the IDI-2 family of proteins. 
 For obtaining FMN-bound forms of IDI-2EF, we have done the crystallization 
screening for IDI-2EF and the crystal pictures and crystallization conditions are shown in 
Figure 8.5. After condition optimization, we were able to obtain bigger yellow crystals 
under conditions containing 0.4 to 0.6 M NH4H2PO4 (Fig. 8.6), and the diffraction data 
was collect on the home source X-ray equipment. After the structure calculation and 
refinement, we could not see a distinct shape of the FMN cofactor in the active site (Data 
not shown). This result may result from the phosphate competition, or the oxidized FMN 

















Table 8.1Structural statistics table of apo-IDI-2EF* 
Data Collection    
 Ligands  ---  
 Crystal conditions  Flash-Cooled at 100K  
 X-ray source and detector  home source_moe  
 Wavelength  (Å )  1.54  
 Space Group  P42
1
2  
 mosaicity  0.88  
 Unit Cell dimensions:    
 a, b, c (Å )  118.5, 118.5, 54.8  
 α=β=γ (°)  90  
Data Processing Statistics  Overall [Last Shell]  
 Resolution range (Å )  30 - 2.5 [2.59 - 2.50]  
 No. reflection recorded  148,060  
 No.  averaged reflections   14,065  
 Redundancy (x-fold)  10.6 [10.5]  
 R
merge
 (%)  12.9 [72.7]  
 <I>/<σI>  16.7 [2.76]  
 Completeness (%)
a  99.4 [100]  
Refinement    
 Resolution Range (Å )  29.6 - 2.5  
 No. Reflections in Working Set 18,026  








c  20.8  
 Average B-factor (Å ²)    
     Protein  46.53  
     Solvent  36.21  
     Ligand  ---  
 No. of Atoms    
     Protein  4751  
     Solvent  27  
     Ligand  ---  
 Occupancy of ligand      RMSD from ideal geometry:    
     Bond Lengths (Å )  0.002  
     Bond Angles (degrees)  0.553  
 Ramachandran Plot    
     Most Favored (%)  95.1  
     Allowed (%)  3.92  










Figure 8.4 The cartoon model of the apo-IDI-2EF crystal structure. (a) A protein 
macromolecule in an asymmetric unit. (b) The total eight polypeptide chains in the unit 









Figure 8.5 IDI-2EF crystallization screening. There are nine crystallization conditions 
for the growth of yellow protein crystals after the crystallization screening of IDI-2EF. 
Conditions are listed as followings. (Class-I-C1: 0.4 M Ammonium phosphate; Class-I-
C2: 1 M Ammonium phosphate, 0.1M tri-sodium citrate pH 5.6; JCSG-II-C12: 0.1M 
sodium citrate pH 5.5, 50% PEG 200; JCSG-II-E2: 0.1M MES pH 5.0, 10% MPD; 
JCSG-II-F10: 0.1M citric acid pH 4.0, 0.8 M ammonium sulfate; JCSG-II-H9: 0.4 M 
ammonium dihydrogen phosphate; JCSG-III-C11: 0.1M Tris pH 7.0; 15% Ethanol; 
JCSG-III-F2: 0.1M sodium citrate pH 5.5, 35% ethoxyethanol; JCSG-III-F12: 0.1M 







Figure 8.6 IDI-2EF crystallization. The protein was dissolved in the buffer containing 
Tris (25 mM pH 7.5), NaCl (100 mM) and imidazole (15 mM). The reservoir contains 
NH4H2PO4 (0.6M, pH 4) and MES (100mM, pH 5.5). The protein-to-reservoir ratio in the 




























 There were some conditions identified from the crystallization screening under 
which yellow crystals of IDI-2EF grew within two days (Fig. 8.5). Because the oxidized 
FMN cofactor is yellow in solution, it suggests that yellow crystals would have oxidized 
FMN binding to the active site of IDI-2EF. In the literature, the FMN molecule can be 
reduced by DTT, NADH or sodium thiosulfate (Na2S2O3). In our crystallization buffer, 
we added 1 mM DTT to remain the reducing environment, but the crystals were yellow, 
suggesting DTT may not be a strong or suitable for preparing a reduced FMN molecule 
under those crystallization conditions. In the future, we might perform crystallization 
screening again and utilize other reducing agents, and we will also look into the 
conditions under which colorless crystals form because those crystals may contain 


















Appendix Table 1 List of structures of MDDEF and IDI-2EF 
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Appendix Table 1 List of structures of MDDEF and IDI-2EF-continued 
/net/stauffacher/chen924/data/MDD/Synch
rotron/23IDB_2014_06_20/Native/A9_x 









































































































































































































































































































































































































































































































































































































FMN, IPP --- 
152 
 









*The diffraction data sets of MDDEF and IDI-2EF in Kandinsky; structures obtained from 
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